MeSH term
Frequency | Condition_Probility | *Cleavage Stage, Ovum | 2 | 1.0 |
Embryo Transfer/*standards | 2 | 1.0 |
Female | 169 | 0.0 |
Humans | 1283 | 0.0 |
Meta-Analysis | 2 | 1.0 |
Pregnancy | 22 | 0.0 |
Pregnancy Outcome | 2 | 0.0 |
Pregnancy Rate | 2 | 1.0 |
Pregnancy, Multiple | 2 | 1.0 |
Randomized Controlled Trials | 2 | 0.0 |
Review Literature | 2 | 1.0 |
Acute Disease | 10 | 0.0 |
Adult | 146 | 0.0 |
Bone Marrow Transplantation/*statistics & numerical data | 2 | 2.0 |
Comparative Study | 98 | 0.0 |
Cord Blood Stem Cell Transplantation/*statistics & numerical data | 2 | 2.0 |
Fetal Blood/transplantation | 2 | 2.0 |
Leukemia/*therapy | 2 | 1.0 |
Patient Selection | 2 | 1.0 |
Animals | 393 | 0.0 |
Oligonucleotide Array Sequence Analysis | 10 | 0.0 |
Incidence | 2 | 0.0 |
Male | 130 | 0.0 |
Middle Aged | 67 | 0.0 |
Reference Values | 6 | 0.0 |
Risk Factors | 4 | 0.0 |
Biopsy | 7 | 0.0 |
*Gene Expression | 3 | 0.0 |
Anxiety Disorders/*classification/psychology/therapy | 2 | 22.0 |
Child | 32 | 0.0 |
Aged | 39 | 0.0 |
Research Support, Non-U.S. Gov't | 895 | 0.0 |
Gene Library | 6 | 0.0 |
Molecular Sequence Data | 219 | 0.0 |
Mutagenesis, Insertional | 2 | 0.0 |
Polymerase Chain Reaction | 39 | 0.0 |
*Polymorphism, Genetic | 7 | 0.0 |
Sequence Deletion | 9 | 0.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
English Abstract | 22 | 0.0 |
Antiviral Agents/*pharmacology | 5 | 3.0 |
Cell Line | 272 | 1.0 |
Genes, Viral | 4 | 1.0 |
HIV-1/*drug effects/physiology | 18 | 20.0 |
Peptide Fragments/pharmacology | 6 | 2.0 |
Receptors, CCR5/antagonists & inhibitors | 4 | 44.0 |
Receptors, CXCR4/antagonists & inhibitors | 6 | 54.0 |
Virus Replication/drug effects | 28 | 11.0 |
Antigens, Surface/metabolism | 3 | 2.0 |
CD4 Lymphocyte Count | 27 | 1.0 |
CD4-Positive T-Lymphocytes/*immunology/metabolism/virology | 2 | 50.0 |
Cells, Cultured | 265 | 1.0 |
HIV-1/*immunology | 37 | 7.0 |
L-Selectin/metabolism | 2 | 6.0 |
*Lectins, C-Type | 5 | 2.0 |
Lymphocyte Function-Associated Antigen-1/metabolism | 4 | 8.0 |
Receptors, Lymphocyte Homing/metabolism | 3 | 8.0 |
Research Support, U.S. Gov't, P.H.S. | 530 | 0.0 |
T-Lymphocyte Subsets/immunology | 3 | 0.0 |
Adolescent | 26 | 0.0 |
Chemokines, CXC/blood/genetics | 2 | 100.0 |
DNA/analysis | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
Leukocytes, Mononuclear/*metabolism | 3 | 2.0 |
*Oligonucleotide Array Sequence Analysis | 3 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 77 | 1.0 |
DNA, Complementary/genetics | 6 | 0.0 |
Gene Expression | 36 | 0.0 |
HIV-1/*pathogenicity/physiology | 14 | 45.0 |
Receptors, CCR5/genetics/physiology | 5 | 71.0 |
Receptors, CXCR4/genetics/physiology | 5 | 83.0 |
Receptors, HIV/genetics/*physiology | 4 | 50.0 |
Transfection | 91 | 0.0 |
Anti-HIV Agents/*chemistry/*pharmacology | 2 | 25.0 |
Binding Sites | 40 | 0.0 |
Drug Design | 7 | 2.0 |
HIV Envelope Protein gp120/drug effects | 3 | 50.0 |
HIV Envelope Protein gp41/drug effects | 2 | 66.0 |
HIV Infections/*drug therapy | 6 | 2.0 |
HIV Integrase Inhibitors/chemistry/pharmacology | 2 | 66.0 |
HIV Protease Inhibitors/chemistry/pharmacology | 2 | 40.0 |
Molecular Structure | 7 | 0.0 |
Reverse Transcriptase Inhibitors/chemistry/pharmacology | 2 | 66.0 |
Trans-Activation (Genetics)/drug effects | 3 | 1.0 |
Epithelial Cells/metabolism/*virology | 2 | 66.0 |
Flow Cytometry | 141 | 2.0 |
HIV-1/*physiology | 101 | 21.0 |
Receptors, CCR5/analysis | 20 | 40.0 |
Receptors, CXCR4/*analysis | 11 | 84.0 |
Virus Replication | 106 | 12.0 |
Base Sequence | 69 | 0.0 |
*Cell Adhesion Molecules | 4 | 1.0 |
Fluorescent Antibody Technique | 13 | 0.0 |
HIV-1/*metabolism | 36 | 15.0 |
RNA, Messenger/analysis | 35 | 1.0 |
Receptors, Chemokine/genetics/*metabolism | 16 | 34.0 |
Receptors, Virus/genetics/*metabolism | 4 | 12.0 |
Sequence Alignment | 30 | 0.0 |
Amino Acid Sequence | 185 | 0.0 |
CD4-Positive T-Lymphocytes | 9 | 3.0 |
*Evolution, Molecular | 7 | 1.0 |
*Gene Deletion | 3 | 0.0 |
Gene Products, nef/*genetics | 2 | 33.0 |
HIV Envelope Protein gp120/genetics | 14 | 41.0 |
HIV-1/genetics/metabolism/*pathogenicity | 3 | 27.0 |
Hela Cells | 77 | 1.0 |
Peptide Fragments/genetics | 11 | 16.0 |
Receptors, CCR5/metabolism | 83 | 56.0 |
Sequence Analysis, DNA | 17 | 0.0 |
Survivors | 2 | 2.0 |
Virulence | 9 | 3.0 |
Antigens, CD27/metabolism | 2 | 15.0 |
Cell Differentiation | 33 | 1.0 |
HIV Infections/physiopathology/*virology | 2 | 40.0 |
Infant | 28 | 0.0 |
Infant, Newborn | 22 | 0.0 |
Receptors, CXCR4/metabolism | 113 | 72.0 |
T-Lymphocytes/physiology/virology | 2 | 50.0 |
Thymus Gland/cytology/*virology | 2 | 33.0 |
Virus Replication/*drug effects | 18 | 11.0 |
Bone Marrow/metabolism | 4 | 3.0 |
Bone Marrow Cells/metabolism | 4 | 4.0 |
Cell Movement | 34 | 4.0 |
Chemokines, CXC/genetics/*metabolism | 6 | 37.0 |
Gene Expression/drug effects | 7 | 0.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 4 | 3.0 |
Mice | 178 | 0.0 |
Mice, Inbred BALB C | 21 | 0.0 |
RNA, Messenger | 2 | 0.0 |
Receptors, CXCR4/genetics/*metabolism | 46 | 97.0 |
Stromal Cells/*metabolism | 4 | 11.0 |
*Up-Regulation | 9 | 3.0 |
Case-Control Studies | 8 | 0.0 |
Cell Movement/drug effects/physiology | 4 | 6.0 |
Down-Regulation | 44 | 2.0 |
Immunoblotting | 3 | 0.0 |
Lymphocyte Activation/drug effects | 5 | 0.0 |
RANTES/*pharmacology | 5 | 29.0 |
Sensitivity and Specificity | 7 | 0.0 |
Chemokines/*physiology | 7 | 22.0 |
CD4-Positive T-Lymphocytes/*metabolism/virology | 3 | 27.0 |
HIV Infections/immunology/metabolism/virology | 3 | 100.0 |
Receptors, CCR5/*metabolism | 71 | 47.0 |
Receptors, CXCR4/*metabolism | 149 | 93.0 |
Epithelial Cells/metabolism | 4 | 1.0 |
RNA, Messenger/metabolism | 36 | 0.0 |
Receptors, Chemokine/*biosynthesis/genetics | 4 | 13.0 |
Receptors, HIV/*biosynthesis/genetics | 2 | 66.0 |
Specific Pathogen-Free Organisms | 3 | 3.0 |
Anti-HIV Agents/*pharmacology | 34 | 24.0 |
Culture Media, Conditioned/pharmacology | 3 | 1.0 |
Down-Regulation/immunology | 5 | 5.0 |
HIV Infections/immunology/prevention & control/virology | 2 | 50.0 |
HIV-1/*immunology/isolation & purification | 3 | 11.0 |
Immune Sera/pharmacology | 3 | 3.0 |
*Proteins | 2 | 0.0 |
Receptors, CXCR4/antagonists & inhibitors/biosynthesis/*physiology | 3 | 100.0 |
Solubility | 9 | 0.0 |
Tumor Cells, Cultured | 120 | 0.0 |
Calcium/blood | 2 | 0.0 |
Chemotaxis, Leukocyte/*physiology | 2 | 6.0 |
Ligands | 55 | 2.0 |
Lymphocytes/immunology | 3 | 0.0 |
Phylogeny | 25 | 1.0 |
RANTES/genetics | 2 | 13.0 |
Sequence Homology, Amino Acid | 33 | 0.0 |
Antigens, CD45/analysis | 4 | 1.0 |
CD4-Positive T-Lymphocytes/immunology/metabolism/virology | 2 | 20.0 |
*Immunologic Memory | 2 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 62 | 0.0 |
T-Lymphocyte Subsets/*immunology/metabolism/*virology | 2 | 100.0 |
Antigens, CD14/immunology | 2 | 3.0 |
CHO Cells | 23 | 1.0 |
Hamsters | 27 | 0.0 |
Lymphocyte Activation/drug effects/*immunology | 2 | 4.0 |
Alleles | 9 | 0.0 |
Antigens, CD8 | 2 | 0.0 |
Homozygote | 10 | 0.0 |
Receptors, CCR5/genetics/*metabolism | 10 | 25.0 |
DNA Primers | 23 | 0.0 |
HIV Envelope Protein gp120/chemistry | 2 | 28.0 |
HIV-1/*genetics | 10 | 3.0 |
Peptide Fragments/chemistry | 3 | 1.0 |
Phenotype | 60 | 0.0 |
*Antiretroviral Therapy, Highly Active | 6 | 1.0 |
HIV Infections/*drug therapy/virology | 3 | 3.0 |
HIV-1/*genetics/metabolism | 3 | 11.0 |
Amino Acid Motifs | 6 | 0.0 |
*Apoptosis/drug effects | 4 | 3.0 |
Jurkat Cells | 38 | 2.0 |
Leukocytes, Mononuclear/immunology | 5 | 1.0 |
Anti-HIV Agents/chemistry/*therapeutic use | 2 | 66.0 |
Calcium Signaling | 7 | 8.0 |
Cell Division/drug effects | 16 | 0.0 |
Cell-Free System | 2 | 0.0 |
Coculture Techniques | 26 | 3.0 |
Gels | 2 | 2.0 |
In Vitro | 40 | 0.0 |
Mitogens/pharmacology | 5 | 1.0 |
Rabbits | 12 | 0.0 |
Temperature | 6 | 0.0 |
Cell Division/drug effects/physiology | 2 | 0.0 |
Mice, Inbred NOD | 19 | 8.0 |
Mice, SCID | 39 | 5.0 |
Xenograft Model Antitumor Assays | 2 | 0.0 |
Phosphorylation/drug effects | 5 | 0.0 |
Genetic Complementation Test | 3 | 0.0 |
HIV-1/genetics/*physiology | 16 | 14.0 |
*Membrane Fusion | 6 | 16.0 |
Receptors, CCR5/*physiology | 23 | 56.0 |
Enzyme-Linked Immunosorbent Assay | 16 | 0.0 |
HIV/*physiology | 5 | 6.0 |
Immunohistochemistry | 56 | 0.0 |
Microglia/*virology | 2 | 40.0 |
Papio | 2 | 1.0 |
RNA, Messenger/genetics | 14 | 0.0 |
Receptors, Chemokine/genetics/*physiology | 3 | 27.0 |
SIV/*physiology | 6 | 22.0 |
Chondroitin Sulfates/metabolism | 2 | 6.0 |
Dogs | 10 | 0.0 |
Membrane Fusion/*physiology | 6 | 23.0 |
*Protein Processing, Post-Translational | 3 | 1.0 |
Brain/immunology/*virology | 2 | 66.0 |
Disease Models, Animal | 11 | 0.0 |
HIV-1/genetics/*pathogenicity | 5 | 26.0 |
Macaca mulatta | 28 | 6.0 |
Macaca nemestrina | 2 | 6.0 |
Macrophages/drug effects/virology | 2 | 100.0 |
Recombinant Proteins/pharmacology | 14 | 0.0 |
SIV/genetics/*pathogenicity | 4 | 50.0 |
Species Specificity | 14 | 0.0 |
Antigens, CD34/analysis | 13 | 2.0 |
Biological Markers/analysis | 5 | 0.0 |
Blood Platelets/*physiology | 2 | 1.0 |
Bone Marrow Cells/cytology | 3 | 3.0 |
Cell Adhesion/*physiology | 2 | 1.0 |
Cell Division | 22 | 0.0 |
Cell Survival | 14 | 1.0 |
Chemotaxis/*physiology | 10 | 29.0 |
HL-60 Cells | 10 | 1.0 |
Phosphoproteins/metabolism | 6 | 0.0 |
Phosphorylation | 38 | 0.0 |
Antibodies, Monoclonal | 7 | 0.0 |
Basophils/*immunology | 2 | 9.0 |
Child, Preschool | 21 | 0.0 |
Mast Cells/*immunology | 2 | 7.0 |
Antigens, CD4/*genetics | 2 | 3.0 |
Cell Line, Transformed | 28 | 1.0 |
*Genetic Vectors/genetics | 2 | 50.0 |
Receptors, CXCR4/*genetics | 23 | 88.0 |
*Transduction, Genetic | 2 | 2.0 |
Anti-HIV Agents/*therapeutic use | 8 | 1.0 |
Antigens, CD4/analysis | 6 | 1.0 |
Antiretroviral Therapy, Highly Active | 9 | 2.0 |
CD4-Positive T-Lymphocytes/immunology/*virology | 5 | 21.0 |
HIV-1/*immunology/physiology | 3 | 8.0 |
Lymphocyte Subsets | 4 | 2.0 |
Receptors, CXCR4/analysis | 25 | 71.0 |
Cell Communication/physiology | 2 | 2.0 |
Chemotaxis, Leukocyte/physiology | 2 | 10.0 |
Receptors, Chemokine/*physiology | 12 | 29.0 |
Antigens, CD4/*metabolism | 37 | 11.0 |
Immunohistochemistry/methods | 3 | 0.0 |
Macrophages/metabolism | 10 | 3.0 |
Rats | 52 | 0.0 |
Rats, Sprague-Dawley | 10 | 0.0 |
Receptors, Chemokine/*metabolism | 44 | 30.0 |
Receptors, HIV/metabolism | 11 | 34.0 |
Cell Adhesion/immunology | 5 | 2.0 |
Chemokines, CXC/*physiology | 23 | 57.0 |
Fibronectins/*metabolism | 2 | 2.0 |
Immunoglobulins/*metabolism | 2 | 3.0 |
Immunologic Memory | 19 | 6.0 |
Interphase/immunology | 4 | 8.0 |
Up-Regulation/immunology | 10 | 6.0 |
Chemokines, CXC/blood | 2 | 50.0 |
Lymphocyte Activation | 31 | 0.0 |
T-Lymphocyte Subsets/immunology/*metabolism | 5 | 14.0 |
Binding, Competitive | 15 | 0.0 |
Chemokines, CXC/*chemistry | 3 | 75.0 |
Circular Dichroism | 6 | 1.0 |
Protein Structure, Secondary | 10 | 0.0 |
Radioligand Assay | 3 | 0.0 |
Receptors, CXCR4/agonists/*metabolism | 2 | 100.0 |
Anti-HIV Agents/pharmacology | 20 | 44.0 |
HIV Protease Inhibitors/pharmacology | 2 | 15.0 |
Macaca | 7 | 8.0 |
Membrane Fusion/drug effects | 7 | 21.0 |
Receptors, CCR5/physiology | 19 | 61.0 |
Reverse Transcriptase Inhibitors/pharmacology | 4 | 26.0 |
SIV/physiology | 2 | 16.0 |
Signal Transduction | 64 | 1.0 |
Structure-Activity Relationship | 34 | 1.0 |
Chemokines, CXC/pharmacology | 45 | 64.0 |
Chemotaxis, Leukocyte | 11 | 6.0 |
HIV Infections/*virology | 30 | 30.0 |
Models, Animal | 2 | 0.0 |
RANTES/pharmacology | 19 | 35.0 |
Spleen/immunology | 3 | 1.0 |
T-Lymphocytes/immunology | 14 | 1.0 |
Mice, Inbred C57BL | 12 | 0.0 |
Microscopy, Confocal | 10 | 1.0 |
Microscopy, Video | 2 | 2.0 |
Vascular Cell Adhesion Molecule-1/metabolism | 5 | 6.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
*HIV-1/physiology | 4 | 22.0 |
Receptors, CCR5/*antagonists & inhibitors | 7 | 20.0 |
Viral Load | 24 | 2.0 |
Calcium Signaling/drug effects | 8 | 16.0 |
HIV-1/drug effects | 7 | 17.0 |
Inhibitory Concentration 50 | 3 | 1.0 |
Microbial Sensitivity Tests | 6 | 2.0 |
Models, Molecular | 24 | 0.0 |
Receptors, CXCR4/*antagonists & inhibitors | 24 | 88.0 |
Apoptosis | 18 | 1.0 |
Calcium/metabolism | 81 | 5.0 |
Chemokines, CXC/*metabolism | 28 | 52.0 |
*Gene Expression Regulation, Neoplastic | 7 | 0.0 |
RNA, Messenger/genetics/metabolism | 18 | 0.0 |
*Signal Transduction | 15 | 0.0 |
Antibodies, Monoclonal/metabolism | 12 | 3.0 |
Chemokines, CXC/*metabolism/pharmacology | 7 | 70.0 |
Macromolecular Substances | 5 | 0.0 |
Polysaccharides/*metabolism | 3 | 13.0 |
Precipitin Tests | 9 | 0.0 |
U937 Cells | 11 | 2.0 |
Arthritis, Rheumatoid/*immunology | 3 | 1.0 |
Cell Movement/immunology | 7 | 7.0 |
Chemokines/metabolism | 14 | 19.0 |
Monocyte Chemoattractant Protein-1/metabolism | 8 | 13.0 |
RANTES/metabolism | 12 | 19.0 |
Receptors, Chemokine/metabolism | 29 | 25.0 |
T-Lymphocytes/*immunology | 8 | 0.0 |
Carcinoma, Renal Cell/*genetics | 2 | 2.0 |
*Gene Expression Profiling | 5 | 1.0 |
Gene Expression Regulation, Neoplastic | 8 | 0.0 |
Kidney Neoplasms/*genetics | 2 | 0.0 |
Neovascularization, Pathologic/*genetics | 2 | 4.0 |
Binding Sites, Antibody/drug effects | 2 | 16.0 |
Calcium/antagonists & inhibitors/metabolism | 2 | 18.0 |
Chemokines, CXC/antagonists & inhibitors/metabolism | 2 | 100.0 |
Clone Cells | 8 | 0.0 |
Cyclodextrins/pharmacology | 2 | 7.0 |
Intracellular Fluid/metabolism | 6 | 5.0 |
*beta-Cyclodextrins | 2 | 4.0 |
Antigens, CD29/metabolism | 2 | 3.0 |
Hematopoietic Stem Cells | 2 | 3.0 |
Proto-Oncogene Protein c-kit/metabolism | 3 | 6.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Transduction, Genetic | 9 | 2.0 |
CD4-Positive T-Lymphocytes/*drug effects/metabolism | 2 | 22.0 |
Gene Expression/*drug effects | 2 | 0.0 |
HIV Envelope Protein gp120/*metabolism | 22 | 13.0 |
Membrane Fusion/*drug effects | 10 | 34.0 |
Receptors, CXCR4/*biosynthesis | 30 | 96.0 |
Antigens, CD/analysis | 5 | 0.0 |
Chemotaxis/immunology | 5 | 35.0 |
Immunophenotyping | 23 | 0.0 |
Lymph Nodes/pathology/virology | 2 | 25.0 |
Cell Culture Techniques | 7 | 1.0 |
Endothelial Growth Factors/pharmacology | 2 | 1.0 |
Endothelium, Vascular/*cytology/drug effects/metabolism | 2 | 10.0 |
Fibroblast Growth Factor 2/pharmacology | 3 | 1.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
Lymphokines/pharmacology | 2 | 1.0 |
Neovascularization, Pathologic/metabolism/pathology | 2 | 8.0 |
Neovascularization, Physiologic/drug effects | 2 | 2.0 |
Vascular Endothelial Growth Factor A | 6 | 0.0 |
Vascular Endothelial Growth Factors | 6 | 0.0 |
Cytokines/*pharmacology | 4 | 1.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 7 | 4.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 7 | 1.0 |
Interferon Type II/pharmacology | 6 | 1.0 |
Neutrophils/*metabolism | 3 | 1.0 |
Receptors, CXCR4/*biosynthesis/genetics | 10 | 90.0 |
Amino Acid Substitution | 12 | 0.0 |
GTP-Binding Proteins/metabolism | 9 | 3.0 |
Genes, Reporter | 17 | 0.0 |
Heterocyclic Compounds/*pharmacology | 11 | 73.0 |
Oligopeptides/*pharmacology | 3 | 3.0 |
Open Reading Frames | 4 | 0.0 |
*Point Mutation | 3 | 0.0 |
Protein Conformation | 30 | 0.0 |
Recombinant Proteins/metabolism | 17 | 0.0 |
Variation (Genetics) | 18 | 1.0 |
*Virus Replication | 22 | 7.0 |
Astrocytes/cytology/virology | 3 | 75.0 |
Disease Progression | 32 | 1.0 |
Disease Transmission, Vertical | 9 | 10.0 |
Prospective Studies | 3 | 0.0 |
Receptors, HIV/*metabolism | 24 | 37.0 |
Time Factors | 56 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism/pharmacology | 2 | 5.0 |
*Down-Regulation | 8 | 2.0 |
HIV Infections/prevention & control | 3 | 20.0 |
Monocytes/immunology/*metabolism | 3 | 6.0 |
Genotype | 28 | 0.0 |
HIV Envelope Protein gp120/chemistry/*genetics | 3 | 42.0 |
HIV-1/classification/*genetics | 4 | 19.0 |
Peptide Fragments/chemistry/*genetics | 2 | 40.0 |
Protein Structure, Quaternary | 2 | 1.0 |
*Variation (Genetics) | 7 | 0.0 |
Cats | 18 | 5.0 |
Genes, env/genetics | 2 | 16.0 |
Leukocytes, Mononuclear/virology | 26 | 24.0 |
Recombinant Fusion Proteins | 2 | 0.0 |
Cell Fusion | 25 | 10.0 |
HIV Envelope Protein gp120/metabolism/*pharmacology | 3 | 33.0 |
Mutagenesis, Site-Directed | 17 | 0.0 |
Protein Structure, Tertiary | 15 | 0.0 |
Receptors, Chemokine/genetics | 3 | 6.0 |
Recombinant Fusion Proteins/metabolism | 9 | 0.0 |
Up-Regulation | 35 | 1.0 |
Bone Marrow/physiology | 3 | 9.0 |
Leukemia, Myelocytic, Acute/metabolism/*pathology | 2 | 16.0 |
Neoplasm Transplantation | 5 | 0.0 |
Receptors, CXCR4/biosynthesis/*physiology | 3 | 100.0 |
Transplantation, Heterologous | 9 | 0.0 |
Anti-HIV Agents/chemistry/*pharmacology | 7 | 35.0 |
Cell Survival/drug effects | 8 | 0.0 |
DNA, Viral/metabolism | 4 | 4.0 |
Transcription, Genetic | 19 | 0.0 |
Virus Integration | 4 | 6.0 |
Virus Latency | 3 | 5.0 |
HIV Envelope Protein gp41/*metabolism | 4 | 22.0 |
Viral Fusion Proteins/*metabolism | 4 | 33.0 |
HIV Infections/*genetics | 5 | 18.0 |
HIV-1/genetics/metabolism/*physiology | 2 | 28.0 |
Macrophages/virology | 22 | 29.0 |
Mutation | 35 | 0.0 |
Pedigree | 2 | 0.0 |
Receptors, CCR5/*genetics | 14 | 8.0 |
T-Lymphocytes/metabolism | 8 | 2.0 |
Tropism | 4 | 30.0 |
Apoptosis/immunology | 5 | 5.0 |
Cell Differentiation/immunology | 13 | 4.0 |
HIV-1/immunology | 3 | 3.0 |
RNA, Messenger/biosynthesis | 21 | 1.0 |
Chemokines, CXC/metabolism | 53 | 67.0 |
*HIV-1 | 48 | 4.0 |
Molecular Conformation | 4 | 1.0 |
Receptors, CXCR4/chemistry/*metabolism | 2 | 100.0 |
HIV Infections/virology | 18 | 25.0 |
HIV-1/metabolism | 3 | 6.0 |
Receptors, CXCR4/immunology/metabolism | 7 | 70.0 |
Green Fluorescent Proteins | 16 | 1.0 |
Heterocyclic Compounds/pharmacology | 22 | 88.0 |
Luminescent Proteins/metabolism | 6 | 1.0 |
Macaca fascicularis | 4 | 1.0 |
Receptors, CXCR4/antagonists & inhibitors/metabolism | 4 | 80.0 |
Receptors, Cytokine/metabolism | 13 | 13.0 |
*Receptors, G-Protein-Coupled | 23 | 9.0 |
Receptors, Peptide/metabolism | 5 | 16.0 |
Receptors, Virus/*metabolism | 11 | 11.0 |
HIV Core Protein p24/biosynthesis | 3 | 6.0 |
HIV-1/isolation & purification/*metabolism | 8 | 50.0 |
*Receptors, Virus | 8 | 33.0 |
HIV Envelope Protein gp120/metabolism | 27 | 17.0 |
Lymphocytes/metabolism | 3 | 1.0 |
Receptors, CXCR4/*physiology | 48 | 97.0 |
Bucladesine/pharmacology | 3 | 1.0 |
Giant Cells/virology | 6 | 15.0 |
Kinetics | 35 | 0.0 |
Promoter Regions (Genetics) | 10 | 0.0 |
Receptors, CXCR4/biosynthesis/*genetics | 6 | 100.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Anti-Inflammatory Agents/*pharmacology | 2 | 2.0 |
Chemokines, CXC/physiology | 14 | 66.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
Up-Regulation/*drug effects | 4 | 5.0 |
*Cell Movement/drug effects | 3 | 25.0 |
Fibronectins | 2 | 9.0 |
Antibodies, Monoclonal/pharmacology | 20 | 2.0 |
Cytosol/metabolism | 2 | 0.0 |
HIV-1/physiology | 11 | 12.0 |
Stromal Cells/metabolism | 9 | 9.0 |
Substrate Specificity | 4 | 0.0 |
*Cell Transformation, Viral | 2 | 1.0 |
Receptors, Cytokine/*metabolism | 6 | 7.0 |
Antibodies, Monoclonal/immunology/metabolism | 6 | 14.0 |
CD4-Positive T-Lymphocytes/immunology/metabolism | 3 | 4.0 |
Conserved Sequence | 8 | 0.0 |
HIV Antibodies/*immunology/metabolism | 2 | 33.0 |
Membrane Fusion | 27 | 20.0 |
Neutralization Tests | 29 | 6.0 |
Chemotaxis | 39 | 21.0 |
Cloning, Molecular | 40 | 0.0 |
GTP-Binding Protein alpha Subunits, Gi-Go/metabolism | 4 | 11.0 |
In Situ Hybridization | 15 | 0.0 |
Receptors, CXCR4/physiology | 36 | 78.0 |
Tissue Distribution | 8 | 0.0 |
ADP-ribosyl Cyclase | 7 | 1.0 |
*Antigens, CD | 10 | 1.0 |
Antigens, Differentiation/*analysis | 2 | 1.0 |
CD4-Positive T-Lymphocytes/*virology | 15 | 18.0 |
NAD+ Nucleosidase/*analysis | 2 | 8.0 |
T-Lymphocyte Subsets/*virology | 2 | 25.0 |
Acquired Immunodeficiency Syndrome/blood/*immunology | 2 | 8.0 |
Chemokines/immunology/*metabolism | 2 | 66.0 |
Platelet Activation | 3 | 2.0 |
Receptors, Chemokine/immunology/*metabolism | 5 | 50.0 |
Receptors, CCR5/*biosynthesis | 12 | 50.0 |
Receptors, CXCR4/biosynthesis | 24 | 72.0 |
Antigens, CD4/metabolism | 47 | 15.0 |
Peptides/*metabolism | 2 | 1.0 |
HIV-1/isolation & purification/*metabolism/physiology | 4 | 66.0 |
Leukocytes, Mononuclear/metabolism/*virology | 3 | 75.0 |
Giant Cells | 15 | 25.0 |
HIV-1/isolation & purification/metabolism/*physiology | 2 | 66.0 |
Tetradecanoylphorbol Acetate/pharmacology | 16 | 0.0 |
Antigens, CD40/*immunology | 3 | 7.0 |
CD40 Ligand/pharmacology | 2 | 7.0 |
Cytokines/biosynthesis | 6 | 1.0 |
Enzyme Activation | 22 | 0.0 |
Macrophage Activation/*immunology | 2 | 6.0 |
Mitogen-Activated Protein Kinases/metabolism | 25 | 2.0 |
CD4-CD8 Ratio | 4 | 0.0 |
Cohort Studies | 15 | 0.0 |
HIV Infections/drug therapy/*metabolism/virology | 2 | 100.0 |
Lectins/pharmacology | 2 | 5.0 |
Immunity, Mucosal | 2 | 2.0 |
Peptide Fragments/chemistry/genetics | 3 | 11.0 |
Receptors, CCR5/chemistry/*immunology | 2 | 40.0 |
Receptors, HIV/*immunology | 4 | 36.0 |
*Cloning, Molecular | 2 | 0.0 |
Protein Isoforms/metabolism | 2 | 1.0 |
Antigens, CD/immunology | 2 | 0.0 |
Cytokines/*immunology | 3 | 3.0 |
*Cytotoxicity, Immunologic | 4 | 0.0 |
Killer Cells, Natural/*immunology | 4 | 0.0 |
Receptors, Immunologic/immunology | 2 | 1.0 |
Signal Transduction/physiology | 7 | 0.0 |
Genome, Viral | 4 | 3.0 |
Membrane Proteins/metabolism | 3 | 0.0 |
Receptors, Virus/metabolism | 9 | 14.0 |
Receptors, CCR5/*analysis | 7 | 36.0 |
Blotting, Western | 25 | 0.0 |
*Cell Adhesion | 2 | 1.0 |
Receptors, CXCR4/*biosynthesis/genetics/*physiology | 3 | 100.0 |
Cell Adhesion | 21 | 1.0 |
Pan troglodytes | 5 | 4.0 |
ADP-ribosyl Cyclase/analysis | 3 | 14.0 |
Antigens, CD19/analysis | 2 | 2.0 |
Antigens, CD27/analysis | 2 | 11.0 |
Bone Marrow/*pathology | 2 | 1.0 |
L-Selectin/analysis | 3 | 15.0 |
Lymph Nodes/*pathology | 2 | 2.0 |
Lymphocyte Count | 11 | 1.0 |
Receptors, Cytokine/analysis | 3 | 20.0 |
Graft Survival/drug effects | 2 | 6.0 |
Genes, env | 9 | 15.0 |
Genes, gag | 2 | 8.0 |
Genes, pol | 2 | 11.0 |
HIV-1/classification/*genetics/isolation & purification | 2 | 25.0 |
Antigens, CD4/analysis/metabolism | 2 | 66.0 |
HIV Core Protein p24/analysis | 6 | 8.0 |
Chemokines, CC/metabolism | 6 | 13.0 |
Consensus Sequence | 4 | 0.0 |
HIV Infections/transmission/*virology | 5 | 45.0 |
Receptors, HIV/chemistry/*metabolism | 2 | 50.0 |
CD4-Positive T-Lymphocytes/virology | 18 | 26.0 |
Cytopathogenic Effect, Viral | 12 | 8.0 |
HIV Envelope Protein gp120/*genetics/metabolism | 6 | 46.0 |
HIV-1/*genetics/*pathogenicity | 2 | 100.0 |
Recombination, Genetic | 10 | 1.0 |
Simian Acquired Immunodeficiency Syndrome/virology | 2 | 25.0 |
Receptors, Formyl Peptide | 4 | 5.0 |
Receptors, Immunologic/metabolism | 2 | 1.0 |
*Receptors, Lipoxin | 4 | 11.0 |
HIV Envelope Protein gp120/*immunology | 7 | 5.0 |
Gene Therapy/*methods | 5 | 1.0 |
Genetic Vectors | 17 | 1.0 |
*HIV-1/genetics | 4 | 7.0 |
Simian virus 40/genetics | 2 | 1.0 |
Dose-Response Relationship, Drug | 45 | 0.0 |
HIV-1/genetics/*metabolism/physiology | 4 | 57.0 |
Bone Marrow/*physiology | 3 | 16.0 |
Granulocyte Colony-Stimulating Factor/*therapeutic use | 2 | 3.0 |
Hematopoietic Stem Cell Mobilization/*methods | 2 | 3.0 |
Hematopoietic Stem Cell Transplantation/*methods | 2 | 2.0 |
Transplantation, Homologous | 3 | 0.0 |
Cell Lineage | 7 | 1.0 |
Chemokines, CXC/biosynthesis/*physiology | 3 | 75.0 |
Cytokines/pharmacology | 12 | 3.0 |
Hematopoietic Stem Cells/cytology | 2 | 2.0 |
Interleukin-7/pharmacology | 2 | 4.0 |
Organ Culture Techniques | 3 | 0.0 |
Signal Transduction/*physiology | 8 | 0.0 |
Blood-Brain Barrier/immunology | 2 | 25.0 |
Cell Movement/*immunology | 10 | 14.0 |
*Cytokines | 3 | 7.0 |
Dendritic Cells/*cytology/immunology | 2 | 4.0 |
RANTES/cerebrospinal fluid | 2 | 66.0 |
Chemokines/*metabolism | 9 | 16.0 |
Liver/pathology | 2 | 1.0 |
Blotting, Northern | 10 | 0.0 |
Cell Membrane/metabolism | 26 | 1.0 |
Chemotactic Factors/*physiology | 3 | 18.0 |
*Gene Expression Regulation | 9 | 0.0 |
NF-kappa B/metabolism | 7 | 0.0 |
Receptors, CXCR4/*genetics/physiology | 2 | 66.0 |
T-Lymphocytes/pathology | 2 | 1.0 |
Actins/metabolism | 14 | 2.0 |
Antigens, CD45 | 2 | 0.0 |
Biological Markers | 8 | 0.0 |
Cell Membrane/immunology | 4 | 1.0 |
Protein-Tyrosine Kinase/metabolism | 10 | 1.0 |
Drug Combinations | 4 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology | 11 | 1.0 |
*Lymphocyte Activation | 6 | 0.0 |
Lymphocyte Culture Test, Mixed | 2 | 0.0 |
Receptors, CCR5/*biosynthesis/genetics | 6 | 40.0 |
Carrier Proteins/*metabolism | 3 | 0.0 |
Peptide Fragments/metabolism | 4 | 1.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
Antigens, CD34/*analysis | 6 | 2.0 |
Antigens, Differentiation/analysis | 4 | 1.0 |
Cell Division/physiology | 9 | 1.0 |
Hematopoietic Stem Cell Mobilization | 8 | 9.0 |
*Hematopoietic Stem Cell Transplantation | 4 | 1.0 |
Hematopoietic Stem Cells/cytology/drug effects/*physiology | 3 | 16.0 |
NAD+ Nucleosidase/analysis | 4 | 9.0 |
Receptors, CXCR4/genetics | 13 | 68.0 |
Thrombopoietin/pharmacology | 4 | 7.0 |
Transplantation, Heterologous/*physiology | 2 | 20.0 |
Antibodies/pharmacology | 5 | 1.0 |
Cell Movement/drug effects/*physiology | 2 | 4.0 |
Chemokines, CXC/*pharmacology/physiology | 3 | 60.0 |
Down-Regulation/*drug effects | 3 | 5.0 |
Pertussis Toxin | 8 | 5.0 |
Protein Binding | 40 | 0.0 |
Receptors, CXCR4/drug effects/*physiology | 6 | 100.0 |
Virulence Factors, Bordetella/pharmacology | 10 | 5.0 |
HIV Long Terminal Repeat/drug effects | 2 | 22.0 |
HIV-1/*drug effects/growth & development | 2 | 14.0 |
Lymphocytes/drug effects/metabolism | 2 | 6.0 |
Monocytes/drug effects/metabolism | 3 | 3.0 |
RNA, Viral/metabolism | 2 | 2.0 |
Up-Regulation/drug effects | 9 | 2.0 |
Antibody Specificity | 7 | 0.0 |
*Disease Transmission, Vertical | 5 | 5.0 |
Antigens, CD4/immunology | 7 | 3.0 |
Chemokines/immunology | 2 | 12.0 |
Dendritic Cells/immunology/*virology | 3 | 30.0 |
Gene Targeting | 5 | 1.0 |
Virulence/immunology | 2 | 18.0 |
HIV Infections/immunology/pathology/*virology | 3 | 50.0 |
Receptors, HIV/immunology | 3 | 30.0 |
Virus Replication/immunology | 14 | 26.0 |
Chemokines, CC/*metabolism | 3 | 5.0 |
Monocytes/immunology | 6 | 1.0 |
Neutrophils/immunology | 2 | 1.0 |
Receptors, CCR5/genetics/metabolism | 10 | 38.0 |
Chemotaxis, Leukocyte/drug effects | 13 | 15.0 |
Flow Cytometry/methods | 4 | 1.0 |
Lymphocytes/*metabolism | 5 | 3.0 |
Prognosis | 7 | 0.0 |
Spleen/pathology | 2 | 2.0 |
1-Phosphatidylinositol 3-Kinase/physiology | 4 | 3.0 |
Cell Line, Tumor | 35 | 1.0 |
Cell Proliferation | 3 | 1.0 |
Receptors, Chemokine/physiology | 8 | 30.0 |
Cell Membrane/immunology/metabolism | 8 | 7.0 |
Chemotaxis, Leukocyte/*immunology | 7 | 15.0 |
Organ Specificity/immunology | 3 | 10.0 |
Receptors, Chemokine/biosynthesis | 5 | 10.0 |
Staining and Labeling | 3 | 0.0 |
Retrospective Studies | 3 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Models, Genetic | 3 | 0.0 |
Neurons/cytology/metabolism | 2 | 2.0 |
Receptors, CXCR4/*biosynthesis/*genetics | 2 | 100.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors | 2 | 2.0 |
Cell Differentiation/drug effects | 13 | 1.0 |
Chromones/pharmacology | 3 | 1.0 |
Drug Synergism | 7 | 0.0 |
Enzyme Inhibitors/pharmacology | 11 | 0.0 |
Megakaryocytes/*cytology | 3 | 5.0 |
Morpholines/pharmacology | 4 | 1.0 |
Proto-Oncogene Proteins/*metabolism | 3 | 0.0 |
Stem Cell Factor/pharmacology | 7 | 4.0 |
Stem Cells/*cytology | 3 | 3.0 |
Stimulation, Chemical | 3 | 0.0 |
COS Cells | 17 | 0.0 |
Antigens, CD4/physiology | 16 | 19.0 |
Dendritic Cells/virology | 3 | 30.0 |
HIV Envelope Protein gp120/physiology | 5 | 27.0 |
Receptors, HIV/*physiology | 21 | 56.0 |
T-Lymphocytes/virology | 21 | 30.0 |
Tropism/*physiology | 4 | 100.0 |
Virus Replication/*physiology | 10 | 19.0 |
Fluorescent Antibody Technique, Indirect | 5 | 0.0 |
Receptors, Cytokine/biosynthesis | 2 | 11.0 |
HIV-1/*drug effects | 13 | 9.0 |
T-Lymphocytes/drug effects/virology | 2 | 33.0 |
Viral Envelope Proteins/*physiology | 2 | 11.0 |
*Genome, Viral | 5 | 7.0 |
South Africa | 4 | 2.0 |
Glycosylation | 13 | 1.0 |
Antigens, CD/*metabolism | 3 | 0.0 |
Antigens, CD40/metabolism | 2 | 3.0 |
Cell Adhesion Molecules/*metabolism | 3 | 1.0 |
Survival Rate | 6 | 0.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
Colony-Forming Units Assay | 10 | 1.0 |
Endothelium, Vascular/cytology/metabolism | 3 | 2.0 |
Hematopoietic Stem Cells/*metabolism | 2 | 1.0 |
Membrane Glycoproteins/analysis | 2 | 0.0 |
Membrane Proteins/analysis | 2 | 1.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/metabolism | 2 | 5.0 |
Radiation Chimera | 3 | 6.0 |
Umbilical Veins | 6 | 1.0 |
Antigens, CD4/biosynthesis/genetics | 3 | 33.0 |
Enzyme Activation/drug effects | 8 | 0.0 |
Gene Expression Profiling | 9 | 0.0 |
Gene Expression Regulation/drug effects | 6 | 0.0 |
Phorbol Esters/*pharmacology | 2 | 5.0 |
Protein Kinase C/metabolism | 4 | 0.0 |
Receptors, CCR5/biosynthesis/genetics | 3 | 33.0 |
Receptors, CXCR4/biosynthesis/genetics | 5 | 71.0 |
Calcium/physiology | 3 | 1.0 |
JNK Mitogen-Activated Protein Kinases | 3 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 3 | 0.0 |
Monocytes/drug effects | 2 | 3.0 |
Protein Processing, Post-Translational | 4 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 4 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 6 | 0.0 |
HIV Envelope Protein gp120/*pharmacology/physiology | 2 | 100.0 |
HIV Infections/complications | 2 | 4.0 |
RNA/metabolism | 2 | 0.0 |
Receptors, Peptide/*physiology | 2 | 22.0 |
Evolution, Molecular | 9 | 1.0 |
HIV-1/*metabolism/pathogenicity | 4 | 21.0 |
Polymorphism, Genetic | 12 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Receptors, CCR5/*genetics/metabolism | 5 | 31.0 |
Receptors, CXCR4/*genetics/metabolism | 6 | 100.0 |
Culture Techniques | 2 | 0.0 |
Herpesvirus 6, Human/*physiology | 2 | 20.0 |
Antibodies, Monoclonal/*immunology | 3 | 0.0 |
HIV-1/*pathogenicity | 21 | 23.0 |
Mice, Nude | 4 | 0.0 |
Receptors, CXCR4/chemistry/*immunology | 3 | 100.0 |
Signal Transduction/immunology | 11 | 3.0 |
Hematopoiesis | 6 | 2.0 |
Hematopoietic Stem Cells/*cytology/drug effects | 2 | 2.0 |
Fibroblasts/metabolism | 3 | 0.0 |
Interleukin-8/*biosynthesis | 3 | 4.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 11 | 2.0 |
Mitogen-Activated Protein Kinase 3 | 12 | 1.0 |
RANTES/*physiology | 2 | 33.0 |
Antibodies, Monoclonal/immunology | 14 | 0.0 |
Cell Count | 5 | 0.0 |
Statistics, Nonparametric | 7 | 0.0 |
Chemotaxis/physiology | 8 | 25.0 |
Culture Media, Serum-Free | 5 | 1.0 |
Interleukin-10/pharmacology | 2 | 2.0 |
Interleukin-13/pharmacology | 2 | 5.0 |
Interleukin-4/pharmacology | 10 | 2.0 |
Protein-Serine-Threonine Kinases/metabolism | 4 | 0.0 |
Quinones/pharmacology | 4 | 2.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
Cell Adhesion/physiology | 5 | 1.0 |
Cell Movement/*physiology | 13 | 6.0 |
Endocytosis | 7 | 1.0 |
GTP-Binding Proteins/*metabolism | 4 | 1.0 |
Ubiquitin/*metabolism | 3 | 1.0 |
*Cell Fusion | 6 | 16.0 |
HIV/*immunology | 4 | 3.0 |
Receptors, CCR5/analysis/physiology | 3 | 75.0 |
Receptors, CXCR4/analysis/physiology | 3 | 100.0 |
Antigens, CD4/*physiology | 10 | 8.0 |
HIV Envelope Protein gp120/chemistry/*physiology | 2 | 33.0 |
HIV-2/*physiology | 9 | 40.0 |
Receptors, CCR5/chemistry/*physiology | 3 | 75.0 |
Tyrosine/metabolism | 4 | 0.0 |
Chemokines, CC/*biosynthesis | 2 | 10.0 |
HIV Envelope Protein gp120/*pharmacology | 10 | 23.0 |
Macrophages/*metabolism | 3 | 1.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 4 | 0.0 |
Cell Polarity | 3 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 2 | 1.0 |
CD8-Positive T-Lymphocytes/*immunology | 5 | 1.0 |
Lymphocyte Activation/immunology | 11 | 2.0 |
HIV-1/*isolation & purification | 3 | 3.0 |
Longitudinal Studies | 11 | 1.0 |
Anti-HIV Agents/pharmacology/*therapeutic use | 3 | 9.0 |
HIV-1/drug effects/physiology | 3 | 18.0 |
Cell Communication | 2 | 0.0 |
Cell Movement/physiology | 6 | 2.0 |
Culture Media, Conditioned | 4 | 1.0 |
Heterotrimeric GTP-Binding Proteins/metabolism | 3 | 8.0 |
*Neoplasm Metastasis | 5 | 6.0 |
Receptors, CXCR4/*biosynthesis/immunology | 6 | 100.0 |
Stromal Cells/physiology | 8 | 15.0 |
*CD4 Lymphocyte Count | 4 | 1.0 |
Brain/*virology | 2 | 16.0 |
Lymphoid Tissue/*virology | 2 | 28.0 |
Macrophages/*virology | 15 | 25.0 |
Gene Expression Regulation, Viral | 5 | 1.0 |
HIV-1/genetics/*metabolism | 8 | 11.0 |
Fibronectins/metabolism | 3 | 1.0 |
Microscopy, Fluorescence | 12 | 0.0 |
Neoplasm Invasiveness | 10 | 0.0 |
Neoplasm Metastasis | 10 | 0.0 |
Receptors, Chemokine/*biosynthesis | 9 | 23.0 |
rac1 GTP-Binding Protein/metabolism | 2 | 2.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Polymerase Chain Reaction/methods | 5 | 0.0 |
Selection (Genetics) | 2 | 1.0 |
Gelatinase A/metabolism | 3 | 5.0 |
Hematopoietic Stem Cells/*cytology | 9 | 4.0 |
Chemokines/*chemistry | 2 | 66.0 |
Plasmids/metabolism | 7 | 0.0 |
Receptors, CXCR4/*chemistry/genetics/*physiology | 2 | 100.0 |
*Virus Assembly | 2 | 8.0 |
Carrier Proteins/metabolism | 4 | 0.0 |
Transforming Growth Factor beta/*pharmacology | 2 | 0.0 |
Antigens, CD/metabolism | 5 | 0.0 |
Cell Separation | 15 | 1.0 |
*Protein-Serine-Threonine Kinases | 11 | 1.0 |
Proto-Oncogene Proteins/metabolism | 9 | 0.0 |
HIV Infections/*immunology | 24 | 5.0 |
Antibodies, Monoclonal/immunology/*pharmacology | 3 | 6.0 |
Gene Products, vpr/genetics | 2 | 50.0 |
Receptors, CCR5/*immunology | 7 | 38.0 |
HIV Envelope Protein gp120/*chemistry/genetics/*metabolism | 3 | 25.0 |
HIV-1/genetics/*pathogenicity/physiology | 5 | 31.0 |
Peptide Fragments/*chemistry/genetics | 2 | 25.0 |
Chemokines, CXC/*pharmacology | 28 | 84.0 |
Guanosine 5'-O-(3-Thiotriphosphate)/metabolism | 3 | 3.0 |
Monocytes/cytology/immunology | 2 | 5.0 |
Cell Transformation, Viral | 3 | 1.0 |
Viral Proteins/genetics/metabolism | 2 | 5.0 |
Fetus/cytology | 2 | 3.0 |
Gene Expression/immunology | 5 | 5.0 |
HIV-1/classification/*growth & development | 2 | 100.0 |
Luciferases/genetics | 3 | 0.0 |
Receptors, CXCR4/genetics/*immunology | 2 | 66.0 |
Serotyping | 2 | 0.0 |
Cell Compartmentation | 4 | 1.0 |
Chemokines, CC | 2 | 66.0 |
Endoplasmic Reticulum/metabolism | 2 | 0.0 |
Golgi Apparatus/metabolism | 2 | 1.0 |
Protein Transport | 2 | 0.0 |
Receptors, CXCR4/genetics/metabolism | 20 | 80.0 |
Receptors, Chemokine/biosynthesis/genetics | 4 | 22.0 |
Breast Neoplasms/therapy | 2 | 13.0 |
Cell Culture Techniques/methods | 2 | 0.0 |
Culture Media | 3 | 0.0 |
Neoplasms/*therapy | 2 | 1.0 |
HIV Infections/*metabolism/virology | 2 | 50.0 |
HIV-1/metabolism/*physiology | 5 | 29.0 |
Macrophage Inflammatory Protein-1/metabolism | 11 | 19.0 |
Thymus Gland/cytology/metabolism | 2 | 13.0 |
Nevirapine/pharmacology | 2 | 66.0 |
Peptide Fragments/*metabolism | 2 | 1.0 |
HIV Envelope Protein gp120/genetics/*metabolism | 17 | 45.0 |
Peptide Fragments/genetics/metabolism | 3 | 2.0 |
Virion/metabolism | 2 | 5.0 |
Cercopithecus aethiops | 12 | 1.0 |
Mutagenesis | 13 | 1.0 |
Xenopus laevis | 4 | 0.0 |
Chemokines, CXC/metabolism/pharmacology | 3 | 37.0 |
HIV Envelope Protein gp120/*toxicity | 3 | 60.0 |
Anti-HIV Agents/*chemical synthesis/chemistry/pharmacology | 3 | 27.0 |
Drug Stability | 2 | 0.0 |
Receptors, CXCR4/*antagonists & inhibitors/chemistry | 2 | 100.0 |
B-Lymphocytes/metabolism | 6 | 3.0 |
Chemokines, CXC/chemistry/*physiology | 2 | 100.0 |
Hematopoiesis/physiology | 3 | 6.0 |
Stem Cells/metabolism | 2 | 2.0 |
Antigens, CD4/drug effects/metabolism | 3 | 37.0 |
Langerhans Cells/metabolism/*virology | 2 | 100.0 |
Receptors, CCR5/drug effects/metabolism | 4 | 100.0 |
Receptors, CXCR4/drug effects/*metabolism | 4 | 80.0 |
Receptors, HIV/drug effects/*metabolism | 3 | 75.0 |
Tumor Necrosis Factor-alpha/pharmacology | 8 | 0.0 |
Apoptosis/*drug effects | 3 | 0.0 |
Drug Interactions | 3 | 0.0 |
Lipids/metabolism | 4 | 1.0 |
Thymus Gland/cytology | 3 | 3.0 |
Treatment Outcome | 4 | 0.0 |
*Chemotaxis, Leukocyte | 4 | 5.0 |
Dimerization | 8 | 0.0 |
Endocytosis/physiology | 2 | 2.0 |
HIV Envelope Protein gp120/*chemistry/genetics | 2 | 50.0 |
HIV-1/genetics/*immunology | 3 | 4.0 |
HIV Infections/*genetics/immunology | 2 | 12.0 |
HIV Seropositivity | 3 | 2.0 |
HIV-1 | 5 | 2.0 |
Haplotypes | 3 | 0.0 |
Biological Assay | 2 | 0.0 |
Dose-Response Relationship, Immunologic | 4 | 0.0 |
Epitopes/immunology | 4 | 0.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 0.0 |
Breast Neoplasms | 2 | 0.0 |
Antigens, CD34/metabolism | 7 | 2.0 |
Chemotaxis/*drug effects | 6 | 12.0 |
Collagen | 3 | 1.0 |
Laminin | 3 | 3.0 |
Mitogen-Activated Protein Kinase 3/metabolism | 2 | 5.0 |
Proteoglycans | 3 | 3.0 |
Bone Marrow/*metabolism | 4 | 8.0 |
Megakaryocytes/*metabolism | 3 | 9.0 |
Cell Differentiation/*immunology | 2 | 7.0 |
Dendritic Cells/*immunology | 3 | 1.0 |
Receptors, Chemokine/immunology | 7 | 21.0 |
Anti-HIV Agents/therapeutic use | 4 | 1.0 |
Receptors, Chemokine/*immunology | 10 | 35.0 |
Virus Replication/*immunology | 5 | 16.0 |
Chemokines/physiology | 9 | 34.0 |
*Endocytosis | 4 | 2.0 |
Gene Products, pol/genetics | 2 | 50.0 |
HIV Long Terminal Repeat | 6 | 4.0 |
Microscopy, Electron | 9 | 0.0 |
Binding, Competitive/drug effects | 4 | 6.0 |
Chemotaxis/drug effects | 18 | 18.0 |
Protein Binding/drug effects | 3 | 0.0 |
Stromal Cells | 5 | 12.0 |
Receptors, CCR5/immunology | 4 | 21.0 |
Receptors, CXCR4/immunology | 4 | 66.0 |
Chimera | 5 | 2.0 |
DNA, Viral | 14 | 8.0 |
In Situ Nick-End Labeling | 4 | 0.0 |
Apoptosis/*physiology | 3 | 0.0 |
HIV Envelope Protein gp120/*physiology | 8 | 25.0 |
HIV-1/*genetics/isolation & purification/*physiology | 2 | 66.0 |
Heterozygote | 6 | 0.0 |
Sequence Analysis | 2 | 0.0 |
Virus Replication/genetics | 4 | 8.0 |
Peptides/chemical synthesis/chemistry/pharmacology | 2 | 33.0 |
Bone Marrow/pathology | 2 | 0.0 |
Cell Adhesion Molecules/physiology | 2 | 2.0 |
Endothelium, Vascular/physiology | 2 | 3.0 |
Graft Survival/*physiology | 2 | 10.0 |
Integrins/physiology | 2 | 2.0 |
Mice, Knockout | 9 | 0.0 |
Protein Kinase C/physiology | 5 | 3.0 |
Chemokines, CC/genetics/pharmacology | 2 | 100.0 |
Gene Therapy/methods | 2 | 2.0 |
Hematopoietic Stem Cells/metabolism | 4 | 3.0 |
T-Lymphocytes/immunology/*metabolism | 2 | 2.0 |
Receptors, CCR5/*chemistry/physiology | 3 | 50.0 |
Receptors, HIV/physiology | 7 | 43.0 |
Bradykinin/pharmacology | 2 | 4.0 |
Chemokines/*metabolism/pharmacology | 3 | 75.0 |
Inflammation/metabolism | 2 | 2.0 |
HIV Envelope Protein gp120/immunology/*physiology | 3 | 42.0 |
HIV Infections/*immunology/virology | 8 | 12.0 |
HIV-1/immunology/*physiology | 3 | 5.0 |
Receptors, CXCR4/biosynthesis/genetics/physiology | 2 | 100.0 |
Th1 Cells/immunology | 4 | 2.0 |
Th2 Cells/immunology | 5 | 3.0 |
Antigens, CD4/genetics/metabolism | 4 | 19.0 |
HIV-1/isolation & purification/*physiology | 3 | 15.0 |
Chemokines/immunology/pharmacology | 2 | 66.0 |
Immunization | 5 | 1.0 |
RNA, Messenger/biosynthesis/genetics | 6 | 1.0 |
Receptors, CXCR4/*biosynthesis/genetics/physiology | 3 | 100.0 |
Chemokines, CXC/metabolism/physiology | 2 | 66.0 |
Receptors, CXCR4/genetics/metabolism/*physiology | 2 | 100.0 |
HIV Infections/complications/*virology | 2 | 66.0 |
HIV-1/drug effects/*metabolism | 2 | 100.0 |
Receptors, CCR5/antagonists & inhibitors/*metabolism | 3 | 75.0 |
Recombinant Proteins/chemistry/metabolism/pharmacology | 2 | 11.0 |
Reproducibility of Results | 2 | 0.0 |
HIV Envelope Protein gp120/pharmacology | 7 | 31.0 |
CD4-Positive T-Lymphocytes/immunology | 9 | 1.0 |
HIV Infections/etiology | 3 | 30.0 |
Receptors, CXCR4/immunology/*physiology | 2 | 100.0 |
Viral Envelope Proteins/immunology/*metabolism | 2 | 28.0 |
Disease Susceptibility | 12 | 1.0 |
HLA-DR Antigens/analysis | 3 | 0.0 |
Antigens, CD4/analysis/genetics | 2 | 18.0 |
DNA, Viral/analysis | 14 | 4.0 |
HIV-1/genetics/*isolation & purification | 2 | 4.0 |
Proviruses/isolation & purification | 2 | 11.0 |
Receptors, CCR5/analysis/genetics | 3 | 75.0 |
Receptors, CXCR4/analysis/genetics | 3 | 100.0 |
Cross-Sectional Studies | 5 | 0.0 |
Receptors, Chemokine/*analysis | 7 | 19.0 |
Antigens, CD45/metabolism | 2 | 2.0 |
CD8-Positive T-Lymphocytes/immunology | 3 | 0.0 |
HIV Infections/*drug therapy/*immunology/virology | 2 | 6.0 |
Genes, Structural | 3 | 0.0 |
Organ Specificity | 11 | 0.0 |
HIV-1/drug effects/*physiology | 8 | 20.0 |
Chemokines/*pharmacology | 10 | 37.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Zidovudine/pharmacology | 3 | 5.0 |
HIV Envelope Protein gp120/*chemistry | 2 | 12.0 |
*Chemokines, CXC | 17 | 26.0 |
T-Lymphocytes/*virology | 13 | 25.0 |
Anti-HIV Agents/*pharmacology/therapeutic use | 6 | 24.0 |
Receptors, CCR5/*drug effects | 2 | 66.0 |
Receptors, CXCR4/*drug effects | 2 | 66.0 |
Chemokines, CXC/*blood | 3 | 42.0 |
Acquired Immunodeficiency Syndrome/immunology | 2 | 2.0 |
Antigens, CD4/*analysis | 3 | 1.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 11 | 2.0 |
*Adaptor Proteins, Signal Transducing | 3 | 0.0 |
Cytoskeletal Proteins/metabolism | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 6 | 0.0 |
Hematopoietic Stem Cells/*physiology | 4 | 3.0 |
Nuclear Proteins/metabolism | 4 | 0.0 |
*Proto-Oncogene Proteins | 2 | 0.0 |
Trans-Activators/metabolism | 3 | 0.0 |
MAP Kinase Signaling System/*physiology | 2 | 2.0 |
Naphthoquinones/*pharmacology | 2 | 9.0 |
Receptors, Chemokine/*drug effects/metabolism | 2 | 100.0 |
Antigens, CD4/biosynthesis | 7 | 8.0 |
CD4-Positive T-Lymphocytes/drug effects/virology | 2 | 28.0 |
Cell Line/drug effects | 2 | 4.0 |
Luciferases/analysis | 2 | 16.0 |
Signal Transduction/drug effects | 15 | 2.0 |
Chimeric Proteins/metabolism | 3 | 1.0 |
Peptide Fragments/chemistry/genetics/*metabolism | 4 | 30.0 |
Antiviral Agents/pharmacology | 3 | 4.0 |
Biological Transport | 3 | 0.0 |
Receptors, CXCR4/drug effects/metabolism | 5 | 83.0 |
HIV-1/*drug effects/*physiology | 2 | 33.0 |
Gene Products, env/*metabolism | 4 | 14.0 |
SIV/*pathogenicity | 5 | 31.0 |
Virion | 3 | 12.0 |
HIV Envelope Protein gp120/genetics/physiology | 2 | 50.0 |
Osteosarcoma | 2 | 2.0 |
Receptors, HIV/genetics | 2 | 20.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
T-Lymphocytes/cytology/immunology | 2 | 2.0 |
Antigens, CD4/genetics/*metabolism | 8 | 17.0 |
HIV Envelope Protein gp41/genetics/*metabolism | 4 | 40.0 |
Quail | 3 | 7.0 |
Calcium Signaling/drug effects/physiology | 2 | 8.0 |
Fetus | 7 | 1.0 |
HIV-1/metabolism/*pathogenicity | 9 | 50.0 |
Macrophage Inflammatory Protein-1/pharmacology | 8 | 18.0 |
Receptors, Chemokine/genetics/metabolism | 6 | 26.0 |
DNA, Viral/genetics | 4 | 2.0 |
Receptor Aggregation/drug effects | 2 | 28.0 |
Gene Products, tat/metabolism | 3 | 8.0 |
CD4-Positive T-Lymphocytes/drug effects/metabolism | 2 | 15.0 |
Macrophages/drug effects/metabolism | 2 | 4.0 |
Equipment Failure Analysis/methods | 2 | 18.0 |
*Epitope Mapping | 2 | 3.0 |
Point Mutation | 3 | 0.0 |
T-Lymphocytes | 3 | 1.0 |
*HIV Long-Term Survivors | 4 | 21.0 |
Receptors, G-Protein-Coupled/metabolism | 4 | 23.0 |
Viremia/*virology | 3 | 18.0 |
Gene Products, env | 2 | 66.0 |
Monocytes/virology | 4 | 14.0 |
Receptors, CXCR4/antagonists & inhibitors/*metabolism | 6 | 100.0 |
Heparitin Sulfate/metabolism | 2 | 5.0 |
Immunodeficiency Virus, Feline/*physiology | 4 | 100.0 |
Membrane Glycoproteins/metabolism | 5 | 0.0 |
Viral Proteins/metabolism | 2 | 2.0 |
RNA Interference | 2 | 0.0 |
RNA, Small Interfering/*genetics | 2 | 15.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Interleukin-10/*pharmacology | 2 | 2.0 |
Pregnancy Complications, Infectious | 2 | 11.0 |
Recombinant Proteins | 2 | 0.0 |
Acquired Immunodeficiency Syndrome/*transmission | 2 | 20.0 |
Monocytes/immunology/virology | 2 | 25.0 |
Immunodeficiency Virus, Feline/*metabolism/physiology | 2 | 100.0 |
Receptors, CXCR4/metabolism/*physiology | 3 | 60.0 |
Receptors, Virus/metabolism/*physiology | 2 | 100.0 |
Recombinant Fusion Proteins/genetics/metabolism | 6 | 0.0 |
T-Lymphocytes/cytology | 3 | 3.0 |
Viral Envelope Proteins/genetics/*metabolism | 3 | 11.0 |
*Cell Movement | 5 | 4.0 |
Endothelium, Vascular/*metabolism | 2 | 0.0 |
Fetal Blood/cytology | 5 | 2.0 |
Neurons/*metabolism/pathology | 2 | 3.0 |
Chronic Disease | 6 | 0.0 |
Antigens, CD4/immunology/metabolism | 4 | 16.0 |
Cytokines/metabolism | 4 | 0.0 |
HIV Envelope Protein gp120/genetics/*physiology | 2 | 33.0 |
Luminescent Proteins/genetics | 2 | 1.0 |
Peptide Fragments/genetics/*physiology | 2 | 20.0 |
Chemokines, CC/metabolism/pharmacology | 3 | 18.0 |
Ethiopia | 3 | 11.0 |
*Prostitution | 2 | 11.0 |
HIV Infections/*therapy | 2 | 6.0 |
Macrophages/immunology/*virology | 4 | 30.0 |
Receptors, CCR5/antagonists & inhibitors/*genetics | 2 | 66.0 |
Antigens, CD26/*metabolism | 4 | 18.0 |
HIV Infections/immunology | 7 | 8.0 |
T-Lymphocytes/pathology/virology | 2 | 100.0 |
Antibodies, Blocking/pharmacology | 2 | 2.0 |
CD4-Positive T-Lymphocytes/*cytology/*immunology/metabolism | 2 | 25.0 |
Caspases/antagonists & inhibitors | 2 | 4.0 |
Chemokines, CXC/antagonists & inhibitors/*physiology | 2 | 66.0 |
Intracellular Fluid/immunology/metabolism | 2 | 6.0 |
Signal Transduction/*immunology | 6 | 1.0 |
Stromal Cells/immunology | 8 | 32.0 |
Up-Regulation/*immunology | 2 | 3.0 |
HIV Antibodies/immunology | 4 | 6.0 |
HIV-1/*metabolism/physiology | 6 | 46.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Thermodynamics | 2 | 0.0 |
HIV Infections/etiology/immunology/virology | 2 | 50.0 |
Antigens, Surface/immunology | 2 | 1.0 |
Breast Neoplasms/*pathology | 3 | 1.0 |
Lymphatic Metastasis | 4 | 0.0 |
Chemokines, CXC/analysis/*metabolism | 2 | 66.0 |
Oligopeptides/pharmacology | 3 | 1.0 |
3T3 Cells | 22 | 1.0 |
HIV Core Protein p24/metabolism | 8 | 20.0 |
Antigens, CD34/biosynthesis | 4 | 4.0 |
Transcription, Genetic/immunology | 2 | 2.0 |
Macrophages/metabolism/*virology | 7 | 31.0 |
Kidney Transplantation/*immunology | 2 | 0.0 |
Nephrectomy | 2 | 2.0 |
Receptors, Cell Surface/metabolism | 4 | 0.0 |
*Disease Models, Animal | 2 | 0.0 |
Receptors, CXCR4/immunology/*metabolism | 6 | 100.0 |
Embryonic and Fetal Development/physiology | 2 | 2.0 |
Hematopoiesis/*drug effects | 2 | 2.0 |
Receptors, CXCR4/analysis/*biosynthesis | 2 | 100.0 |
CD4-Positive T-Lymphocytes/*metabolism | 7 | 7.0 |
HIV Seronegativity/immunology | 3 | 5.0 |
Lipopolysaccharides/pharmacology | 7 | 0.0 |
Mycobacterium tuberculosis/*immunology | 2 | 3.0 |
Chimeric Proteins/genetics/metabolism | 4 | 4.0 |
Gene Products, env/genetics/metabolism | 5 | 35.0 |
CD4-Positive T-Lymphocytes/physiology/*virology | 2 | 40.0 |
Chemokines, CXC/chemistry/*metabolism | 2 | 100.0 |
Bone Marrow Cells/*physiology | 3 | 16.0 |
Aged, 80 and over | 12 | 0.0 |
Intercellular Signaling Peptides and Proteins/metabolism | 2 | 2.0 |
Capillaries/cytology | 2 | 12.0 |
RNA, Messenger/analysis/genetics | 2 | 0.0 |
Chemokines, CXC/*genetics | 6 | 18.0 |
Gene Frequency | 5 | 0.0 |
Immunity, Natural/genetics | 2 | 3.0 |
Receptors, Chemokine/*genetics | 10 | 10.0 |
Cell Movement/drug effects | 20 | 5.0 |
Chemotactic Factors/*pharmacology | 5 | 14.0 |
Magnetic Resonance Spectroscopy | 3 | 0.0 |
Chemokines/pharmacology | 12 | 36.0 |
Binding Sites/genetics | 4 | 0.0 |
HIV/genetics/*metabolism | 2 | 66.0 |
HIV Envelope Protein gp120/genetics/metabolism | 2 | 25.0 |
SIV/genetics/*metabolism | 2 | 33.0 |
CD4-Positive T-Lymphocytes/*immunology/virology | 3 | 12.0 |
Receptors, CCR5/*antagonists & inhibitors/biosynthesis | 2 | 66.0 |
Receptors, CXCR4/*antagonists & inhibitors/biosynthesis | 2 | 100.0 |
Nitriles/pharmacology | 2 | 1.0 |
RNA, Messenger/antagonists & inhibitors/biosynthesis | 2 | 8.0 |
B-Lymphocytes/metabolism/*physiology | 2 | 28.0 |
Integrin alpha4beta1 | 3 | 3.0 |
Integrins/metabolism | 4 | 2.0 |
*Genes, env | 5 | 16.0 |
T-Lymphocytes/metabolism/*virology | 3 | 15.0 |
Phosphotyrosine/metabolism | 2 | 0.0 |
*Ubiquitin-Protein Ligases | 2 | 0.0 |
src-Family Kinases/metabolism | 2 | 1.0 |
CD4-Positive T-Lymphocytes/immunology/*metabolism/virology | 2 | 50.0 |
HIV-1/pathogenicity/physiology | 2 | 25.0 |
Receptors, CCR5/biosynthesis | 10 | 25.0 |
*HIV-1/pathogenicity | 2 | 16.0 |
Ribonucleases/metabolism | 5 | 3.0 |
T-Lymphocytes/immunology/virology | 3 | 16.0 |
CD8-Positive T-Lymphocytes/*virology | 2 | 20.0 |
Receptors, Virus/*physiology | 6 | 15.0 |
HIV-1/*growth & development/immunology | 2 | 40.0 |
Proviruses/*isolation & purification | 2 | 22.0 |
Cell Adhesion/drug effects | 9 | 2.0 |
Chemokines, CXC/genetics/pharmacology | 2 | 100.0 |
Interleukin-2/pharmacology | 5 | 0.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 2 | 1.0 |
Kidney | 5 | 1.0 |
Peptide Fragments/chemistry/*pharmacology | 2 | 6.0 |
Chemokines/*biosynthesis/genetics | 2 | 14.0 |
Fetal Blood/*cytology | 6 | 3.0 |
Hematopoietic Stem Cells/immunology/*virology | 2 | 66.0 |
Enzyme Activation/drug effects/immunology | 2 | 6.0 |
Mice, Inbred Strains | 2 | 0.0 |
Chemokines, CXC/genetics | 2 | 11.0 |
DNA Primers/genetics | 11 | 0.0 |
Virus Replication/drug effects/*physiology | 3 | 60.0 |
Chemotaxis, Leukocyte/immunology | 7 | 12.0 |
Cytokines/biosynthesis/genetics | 2 | 3.0 |
Th1 Cells/immunology/metabolism | 2 | 5.0 |
Th2 Cells/immunology/metabolism | 2 | 5.0 |
*Apoptosis | 11 | 0.0 |
Protein Kinase C/antagonists & inhibitors/*metabolism | 2 | 2.0 |
Acquired Immunodeficiency Syndrome/genetics/*immunology/virology | 2 | 100.0 |
HIV Infections/genetics/*immunology/virology | 3 | 60.0 |
Receptors, Chemokine/analysis | 2 | 6.0 |
Terminology | 2 | 1.0 |
Depression, Chemical | 2 | 1.0 |
Hematopoietic Stem Cells/drug effects/*metabolism | 2 | 10.0 |
Interleukin-3/pharmacology | 3 | 1.0 |
Membrane Glycoproteins/*metabolism | 4 | 0.0 |
Receptors, CXCR4/*analysis/genetics/physiology | 3 | 100.0 |
Acquired Immunodeficiency Syndrome/*virology | 5 | 25.0 |
HIV-1/pathogenicity/*physiology | 10 | 37.0 |
*Brain Chemistry | 2 | 1.0 |
Apoptosis/drug effects | 8 | 1.0 |
Receptors, CXCR4/*blood | 3 | 100.0 |
*Saccharomyces cerevisiae Proteins | 3 | 0.0 |
Cells, Cultured/drug effects | 2 | 2.0 |
Leukemia, Megakaryocytic, Acute/pathology | 2 | 18.0 |
Recombinant Fusion Proteins/physiology | 4 | 1.0 |
Gene Expression Regulation | 11 | 0.0 |
Isoenzymes/metabolism | 4 | 0.0 |
Phospholipase C/metabolism | 4 | 1.0 |
Protein Processing, Post-Translational/drug effects | 3 | 2.0 |
HIV Infections/*transmission | 2 | 3.0 |
Cyclic AMP/metabolism | 4 | 0.0 |
Forskolin/pharmacology | 5 | 1.0 |
HIV Envelope Protein gp41/*pharmacology | 3 | 37.0 |
Peptide Fragments/*pharmacology | 3 | 1.0 |
Receptors, Chemokine/genetics/*immunology | 4 | 40.0 |
Th1 Cells/*immunology | 4 | 2.0 |
Th2 Cells/*immunology | 5 | 3.0 |
Antigens, CD40/immunology | 2 | 3.0 |
Antigens, CD45/biosynthesis/blood | 2 | 40.0 |
Chemokines, CXC/metabolism/*physiology | 4 | 44.0 |
Interleukin-15/pharmacology | 2 | 8.0 |
Antigens, CD4/metabolism/*physiology | 2 | 50.0 |
Cell Migration Inhibition | 5 | 4.0 |
Chemokines, CXC/antagonists & inhibitors/physiology | 2 | 66.0 |
HIV Antibodies/blood | 2 | 2.0 |
HIV-1/pathogenicity | 10 | 50.0 |
Chemokines, CXC/*biosynthesis | 6 | 40.0 |
Leukocytes, Mononuclear/immunology/*virology | 2 | 22.0 |
Macrophages/immunology/virology | 3 | 33.0 |
RANTES/analysis | 4 | 30.0 |
HIV Infections/*immunology/pathology | 2 | 6.0 |
Macrophage Inflammatory Protein-1/analysis | 2 | 33.0 |
HT29 Cells | 2 | 1.0 |
Chemokines, CXC/biosynthesis/genetics | 2 | 25.0 |
Gene Expression Regulation, Neoplastic/drug effects | 2 | 0.0 |
Neoplasm Proteins/biosynthesis/genetics | 2 | 1.0 |
RANTES/biosynthesis/genetics | 2 | 33.0 |
T-Lymphocytes/*drug effects/metabolism | 3 | 8.0 |
Tumor Cells, Cultured/drug effects/metabolism | 2 | 1.0 |
Cytopathogenic Effect, Viral/drug effects | 2 | 8.0 |
Giant Cells/drug effects | 2 | 14.0 |
Protein Biosynthesis | 4 | 0.0 |
Virion/pathogenicity | 2 | 40.0 |
Receptors, CCR5/genetics | 14 | 22.0 |
Chemokines, CC/analysis | 2 | 18.0 |
Interferon Type II/*pharmacology | 5 | 1.0 |
Monocytes/cytology | 4 | 3.0 |
HIV Antigens/*immunology | 4 | 7.0 |
HIV Envelope Protein gp120/immunology | 7 | 8.0 |
Calcium Signaling/immunology | 2 | 9.0 |
Receptors, CXCR4/*biosynthesis/metabolism | 2 | 100.0 |
CD4-Positive T-Lymphocytes/classification/*virology | 2 | 100.0 |
Giant Cells/*virology | 3 | 30.0 |
Receptors, HIV/*genetics | 2 | 20.0 |
T-Lymphocyte Subsets/virology | 2 | 40.0 |
CD4-Positive T-Lymphocytes/physiology | 3 | 5.0 |
HIV-2/*pathogenicity | 2 | 33.0 |
Chemokines, CXC/*biosynthesis/genetics/pharmacology | 2 | 100.0 |
Endothelium, Vascular/cytology/drug effects | 3 | 4.0 |
Neoplasm Staging | 5 | 0.0 |
Receptors, HIV/metabolism/*physiology | 2 | 100.0 |
T-Lymphocytes/*metabolism/virology | 3 | 37.0 |
Receptors, CXCR4 | 19 | 50.0 |
Lymphocytes/metabolism/*virology | 2 | 66.0 |
Receptors, HIV/biosynthesis | 3 | 50.0 |
CD4-Positive T-Lymphocytes/metabolism/*virology | 3 | 17.0 |
Gene Transfer Techniques | 4 | 0.0 |
HIV Seronegativity | 4 | 2.0 |
Chemokines, CXC/biosynthesis | 4 | 16.0 |
Receptors, CXCR4/*biosynthesis/physiology | 2 | 100.0 |
Stromal Cells/immunology/metabolism | 3 | 20.0 |
Cytokines/physiology | 4 | 2.0 |
Receptors, CCR5/biosynthesis/*metabolism | 2 | 66.0 |
T-Lymphocytes/immunology/metabolism | 2 | 1.0 |
Analysis of Variance | 3 | 0.0 |
Chemokines, CXC/*analysis/genetics | 2 | 66.0 |
Taiwan | 2 | 1.0 |
Chemokines, CC/pharmacology | 5 | 16.0 |
Chemotaxis, Leukocyte/*drug effects | 2 | 3.0 |
Tonsil/immunology | 2 | 3.0 |
*Phylogeny | 2 | 1.0 |
*Chemotaxis | 4 | 12.0 |
HIV Infections/*metabolism | 4 | 8.0 |
*Cell Death | 3 | 6.0 |
B-Lymphocytes/immunology/*metabolism | 2 | 3.0 |
Chemokines, CXC/genetics/metabolism | 2 | 33.0 |
Intercellular Signaling Peptides and Proteins/genetics/metabolism | 2 | 9.0 |
Proteoglycans/metabolism | 2 | 2.0 |
Homosexuality, Male | 4 | 4.0 |
Models, Biological | 14 | 0.0 |
Dendritic Cells/*drug effects/physiology | 2 | 16.0 |
HLA-DR Antigens/biosynthesis | 3 | 3.0 |
Hematopoietic Stem Cells/cytology/*immunology | 3 | 6.0 |
HIV-1/classification/genetics/*physiology | 3 | 60.0 |
Mitogen-Activated Protein Kinase 1/*metabolism | 2 | 1.0 |
Antigens, CD34/*metabolism | 4 | 3.0 |
HIV Infections/*prevention & control | 2 | 7.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Acquired Immunodeficiency Syndrome/transmission/*virology | 2 | 100.0 |
Gene Products, env/*genetics/metabolism | 2 | 33.0 |
Mucous Membrane/virology | 2 | 40.0 |
Recombinant Proteins/genetics/metabolism | 3 | 0.0 |
RNA, Viral/analysis | 4 | 1.0 |
Receptors, CCR5/metabolism/*physiology | 2 | 50.0 |
Antibodies | 2 | 0.0 |
Receptors, CCR5/immunology/metabolism | 3 | 27.0 |
Dendritic Cells/*metabolism | 2 | 3.0 |
Receptors, CXCR4/genetics/*physiology | 8 | 88.0 |
Interleukin-1/pharmacology | 4 | 0.0 |
Interleukin-6/pharmacology | 3 | 1.0 |
T-Lymphocytes/*metabolism | 4 | 1.0 |
Cattle | 4 | 0.0 |
Gene Deletion | 7 | 0.0 |
Antigens, CD/physiology | 3 | 1.0 |
B-Lymphocytes/*immunology | 2 | 0.0 |
Receptors, CCR5/deficiency/genetics/physiology | 2 | 100.0 |
Receptors, Cytokine/genetics/*physiology | 2 | 22.0 |
Receptors, Virus/genetics/*physiology | 2 | 40.0 |
Chemokines | 3 | 75.0 |
Gene Products, env/metabolism | 10 | 19.0 |
Lymphocytes | 2 | 1.0 |
RANTES/analogs & derivatives/pharmacology | 2 | 66.0 |
Receptors, HIV/antagonists & inhibitors/*metabolism | 2 | 100.0 |
HIV Infections/blood/*immunology | 2 | 3.0 |
Receptors, CCR5/blood | 2 | 66.0 |
Receptors, CXCR4/blood | 4 | 100.0 |
Receptors, Chemokine/*blood | 3 | 50.0 |
Neurons/physiology | 2 | 1.0 |
Rats, Wistar | 6 | 0.0 |
Interferon-gamma, Recombinant/*pharmacology | 2 | 1.0 |
Interleukin-4/*pharmacology | 4 | 1.0 |
Trophoblasts/cytology/*metabolism | 2 | 9.0 |
Protein Binding/immunology | 3 | 1.0 |
Receptors, Chemokine/*biosynthesis/blood | 2 | 28.0 |
Antigens, CD28/immunology | 2 | 1.0 |
Antigens, CD3/immunology | 4 | 1.0 |
CD4-Positive T-Lymphocytes/cytology/*immunology/*virology | 2 | 50.0 |
HIV-1/growth & development/*immunology | 2 | 33.0 |
Lymphocyte Activation/*immunology | 2 | 0.0 |
Macrophage Inflammatory Protein-1/biosynthesis | 3 | 15.0 |
Primates | 3 | 4.0 |
RANTES/biosynthesis | 3 | 17.0 |
Astrocytes/metabolism | 4 | 5.0 |
Endothelium, Vascular/cytology | 9 | 3.0 |
Intercellular Adhesion Molecule-1/metabolism | 4 | 2.0 |
Monocytes/*metabolism | 2 | 0.0 |
Glycoproteins/genetics/metabolism | 2 | 8.0 |
Rats, Inbred Lew | 2 | 0.0 |
India | 3 | 0.0 |
Nucleic Acid Heteroduplexes | 2 | 4.0 |
HIV Infections/*immunology/*virology | 4 | 16.0 |
Immunity, Cellular | 3 | 0.0 |
T-Lymphocyte Subsets/*immunology | 2 | 0.0 |
Calcium Signaling/physiology | 2 | 5.0 |
Monocytes/*immunology | 3 | 0.0 |
Antibodies/immunology | 6 | 1.0 |
Receptors, CCR5/genetics/immunology/*metabolism | 2 | 40.0 |
Viral Envelope Proteins/metabolism | 2 | 3.0 |
Proviruses | 2 | 11.0 |
Anti-HIV Agents/chemistry/metabolism/*pharmacology | 3 | 75.0 |
Cell Membrane/virology | 3 | 18.0 |
Gene Products, env/physiology | 2 | 25.0 |
Lymphocytes/immunology/*virology | 2 | 50.0 |
Evaluation Studies | 2 | 0.0 |
Leukocytes, Mononuclear/*immunology/*virology | 2 | 66.0 |
Monocytes/*immunology/*virology | 3 | 100.0 |
Receptors, CXCR4/drug effects/genetics/*physiology | 5 | 100.0 |
Lymph Nodes/metabolism | 3 | 5.0 |
Receptors, CCR5/drug effects/genetics/*physiology | 2 | 100.0 |
Intestinal Mucosa/*metabolism | 2 | 2.0 |
Antigens, CD34 | 2 | 0.0 |
HIV/*metabolism | 3 | 8.0 |
Hematopoietic Stem Cells/cytology/metabolism | 2 | 8.0 |
HIV Infections/*etiology | 4 | 33.0 |
Receptors, CXCR4/*biosynthesis/drug effects | 2 | 100.0 |
RNA, Viral/blood | 5 | 0.0 |
Receptors, HIV/analysis | 2 | 50.0 |
HIV Infections/therapy | 2 | 13.0 |
Brain/*blood supply | 3 | 9.0 |
Breast Neoplasms/*metabolism/*pathology | 3 | 8.0 |
Cell Movement/*drug effects | 2 | 2.0 |
Transcription Factors/metabolism | 2 | 0.0 |
RNA, Messenger/drug effects | 3 | 4.0 |
Receptors, Interleukin/metabolism | 4 | 6.0 |
Receptors, Interleukin-8B | 5 | 45.0 |
Drug Resistance, Microbial | 3 | 1.0 |
Genes, Reporter/genetics | 4 | 1.0 |
beta-Galactosidase/metabolism | 2 | 1.0 |
Epitopes | 6 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology/metabolism | 2 | 3.0 |
Inflammation | 3 | 0.0 |
Interleukin-4/*immunology | 2 | 11.0 |
B-Lymphocytes/cytology | 2 | 2.0 |
*DNA-Binding Proteins | 4 | 0.0 |
Proteins/genetics | 2 | 0.0 |
Syndrome | 3 | 0.0 |
*Transcription Factors | 3 | 0.0 |
Receptors, HIV/*biosynthesis | 3 | 60.0 |
Proviruses/genetics | 3 | 4.0 |
Drug Therapy, Combination | 4 | 0.0 |
HIV Envelope Protein gp120/chemistry/genetics | 3 | 25.0 |
HIV-1/genetics/isolation & purification/*physiology | 2 | 11.0 |
Receptors, HIV/genetics/*metabolism | 11 | 55.0 |
Chemokines/*immunology | 9 | 47.0 |
Immunoenzyme Techniques | 5 | 0.0 |
Chemotaxis/drug effects/physiology | 3 | 14.0 |
Recombinant Proteins/immunology/pharmacology | 2 | 8.0 |
Cell Fusion/drug effects | 3 | 15.0 |
MAP Kinase Signaling System/drug effects | 3 | 3.0 |
Receptor Cross-Talk | 2 | 5.0 |
Umbilical Veins/cytology | 7 | 2.0 |
Receptors, CXCR4/*analysis/genetics | 5 | 83.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Caspases/*metabolism | 2 | 0.0 |
Embryo | 3 | 0.0 |
Growth Substances/physiology | 2 | 1.0 |
Hematopoietic Stem Cells/cytology/*drug effects | 4 | 7.0 |
Receptors, CXCR4/drug effects | 3 | 75.0 |
Arrestins/genetics/*metabolism | 2 | 25.0 |
Antigens, Viral/immunology | 2 | 1.0 |
Macrophage Inflammatory Protein-1/*metabolism | 2 | 9.0 |
Peptide Fragments/genetics/*metabolism | 6 | 22.0 |
HIV Core Protein p24/genetics | 3 | 27.0 |
Models, Chemical | 2 | 0.0 |
CD8-Positive T-Lymphocytes/immunology/metabolism | 2 | 4.0 |
Gene Expression Regulation/immunology | 5 | 3.0 |
Receptors, CXCR4/biosynthesis/genetics/*metabolism | 2 | 100.0 |
B-Lymphocytes/immunology/*virology | 3 | 27.0 |
DNA, Viral/biosynthesis | 2 | 3.0 |
Giant Cells/physiology | 2 | 11.0 |
Leukocytes, Mononuclear/*virology | 5 | 14.0 |
Receptors, CXCR4/*immunology | 16 | 100.0 |
Chemokines/secretion | 2 | 15.0 |
HIV-1/*growth & development | 4 | 6.0 |
Monocytes/metabolism | 9 | 2.0 |
Neuroglia/metabolism | 2 | 2.0 |
Receptors, CCR5/metabolism/physiology | 3 | 100.0 |
Receptors, Chemokine/metabolism/*physiology | 2 | 22.0 |
Receptors, CXCR4/*antagonists & inhibitors/physiology | 3 | 100.0 |
Antigens, CD4/genetics | 4 | 7.0 |
Gene Products, env/genetics | 4 | 26.0 |
Phytohemagglutinins/pharmacology | 4 | 0.0 |
Antibodies, Monoclonal/chemistry/immunology | 2 | 18.0 |
HIV-1/genetics/immunology | 2 | 15.0 |
Cell Adhesion Molecules/metabolism | 3 | 1.0 |
Cell Cycle/physiology | 2 | 0.0 |
Chemokines, CC/*pharmacology | 2 | 9.0 |
Neurons/*metabolism | 4 | 1.0 |
HIV-1/*drug effects/immunology/physiology | 2 | 33.0 |
Edema/etiology | 2 | 14.0 |
Emergency Treatment/methods/psychology | 2 | 50.0 |
Finger Injuries/*etiology/therapy | 2 | 50.0 |
Foreign Bodies/*complications | 2 | 50.0 |
Mental Competency | 2 | 50.0 |
Range of Motion, Articular | 2 | 8.0 |
Schizophrenia/*complications | 2 | 20.0 |
Gene Products, env/*genetics | 2 | 25.0 |
HIV-2/pathogenicity | 2 | 100.0 |
NIH 3T3 Cells | 4 | 1.0 |
SIV/pathogenicity | 2 | 50.0 |
Antigens, Surface/analysis | 2 | 0.0 |
Lectins, C-Type/analysis | 2 | 33.0 |
Mannose-Binding Lectins/analysis | 2 | 66.0 |
Acquired Immunodeficiency Syndrome/virology | 5 | 26.0 |
HIV-1/growth & development/metabolism | 3 | 100.0 |
Peptides/metabolism/pharmacology | 2 | 12.0 |
Protein Structure, Tertiary/physiology | 2 | 1.0 |
Leukemia, B-Cell, Chronic/*metabolism/*pathology | 3 | 100.0 |
Stromal Cells/*pathology | 2 | 6.0 |
HIV-1/*chemistry | 3 | 10.0 |
Membrane Fusion/genetics | 2 | 50.0 |
Receptors, Cytokine/genetics/metabolism | 3 | 25.0 |
Peptide Fragments/*genetics/metabolism | 2 | 15.0 |
HIV Infections/immunology/virology | 5 | 19.0 |
Simian Acquired Immunodeficiency Syndrome/immunology/virology | 2 | 40.0 |
CD4-Positive T-Lymphocytes/immunology/virology | 3 | 10.0 |
T-Lymphocytes/drug effects/immunology/*metabolism | 2 | 8.0 |
Chemokines, CXC/pharmacology/*physiology | 3 | 60.0 |
T-Lymphocytes/physiology | 2 | 1.0 |
Colon/*chemistry | 2 | 9.0 |
Endocytosis/drug effects | 3 | 4.0 |
Recombinant Proteins/chemistry/metabolism | 4 | 0.0 |
HIV-1/*immunology/isolation & purification/metabolism | 2 | 100.0 |
Chemokines, CXC/chemistry/*pharmacology | 2 | 66.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Transcription Factors/*metabolism | 4 | 0.0 |
HIV Envelope Protein gp120/*metabolism/pharmacology | 2 | 66.0 |
Adenoviridae/genetics | 3 | 0.0 |
Gene Therapy | 3 | 0.0 |
Liver/metabolism | 4 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Quinolinic Acid/*pharmacology | 2 | 40.0 |
HIV/drug effects/*physiology | 2 | 28.0 |
Th1 Cells/*physiology | 2 | 11.0 |
Receptors, CXCR4/*drug effects/metabolism | 2 | 100.0 |
*Antigens, Differentiation | 2 | 2.0 |
Chemotaxis, Leukocyte/genetics/*immunology | 2 | 40.0 |
Inositol 1,4,5-Trisphosphate/metabolism | 2 | 3.0 |
Antigens, CD4/*immunology | 8 | 2.0 |
Disease Susceptibility/immunology | 4 | 5.0 |
CD4-Positive T-Lymphocytes/metabolism | 4 | 3.0 |
CD8-Positive T-Lymphocytes/metabolism | 2 | 2.0 |
Immunity, Natural | 6 | 2.0 |
Endothelium, Vascular/cytology/drug effects/*metabolism | 2 | 2.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
Interleukin-8/pharmacology | 4 | 8.0 |
Follow-Up Studies | 3 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Receptors, Cytokine/genetics | 2 | 6.0 |
T-Lymphocytes/immunology/*virology | 3 | 18.0 |
Receptors, Chemokine/*biosynthesis/physiology | 4 | 44.0 |
*Pertussis Toxin | 2 | 6.0 |
Antigens, CD45/*metabolism | 2 | 6.0 |
Receptors, HIV/*antagonists & inhibitors | 2 | 28.0 |
Chemokines, CXC/*blood/genetics | 2 | 100.0 |
Receptors, HIV/*analysis | 2 | 40.0 |
HIV Envelope Protein gp120/*genetics | 3 | 12.0 |
HIV Infections/immunology/*virology | 6 | 17.0 |
Peptide Fragments/*genetics | 2 | 4.0 |
Cytokines/*biosynthesis | 3 | 0.0 |
Macrophages/*immunology | 2 | 0.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Cell Death/drug effects | 4 | 2.0 |
Cytokines/genetics/metabolism | 3 | 9.0 |
Anti-HIV Agents/metabolism/*pharmacology | 5 | 35.0 |
*Antimicrobial Cationic Peptides | 4 | 20.0 |
HIV-1/*drug effects/metabolism | 3 | 21.0 |
Heterocyclic Compounds/metabolism | 2 | 40.0 |
Mink | 2 | 3.0 |
Receptors, CXCR4/antagonists & inhibitors/genetics/*metabolism | 3 | 75.0 |
Receptors, CCR5 | 10 | 20.0 |
Viral Envelope Proteins/genetics/metabolism | 2 | 14.0 |
Down-Regulation/drug effects | 8 | 2.0 |
Receptors, CXCR4/biosynthesis/*immunology | 4 | 100.0 |
Signal Transduction/drug effects/immunology | 2 | 4.0 |
Interleukin-4/metabolism | 2 | 2.0 |
AIDS Dementia Complex/*immunology | 2 | 40.0 |
Apoptosis/*immunology | 3 | 1.0 |
*Receptors, Chemokine | 5 | 5.0 |
Brain/*metabolism | 3 | 0.0 |
*Membrane Glycoproteins | 4 | 0.0 |
Genetic Heterogeneity | 2 | 0.0 |
HIV Envelope Protein gp160/genetics/*metabolism | 5 | 83.0 |
Heterocyclic Compounds/chemistry/metabolism/*pharmacology | 2 | 100.0 |
Receptors, CXCR4/*antagonists & inhibitors/metabolism | 6 | 100.0 |
Giant Cells/immunology/virology | 2 | 33.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
AIDS Dementia Complex/physiopathology | 2 | 50.0 |
Macrophage Activation | 3 | 1.0 |
1-Methyl-3-isobutylxanthine/pharmacology | 2 | 2.0 |
Cell Membrane/physiology | 2 | 1.0 |
GTP-Binding Proteins/*physiology | 2 | 1.0 |
Hematopoietic Stem Cells/*immunology/*virology | 3 | 100.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
Acquired Immunodeficiency Syndrome/immunology/*virology | 2 | 15.0 |
Acquired Immunodeficiency Syndrome/*immunology | 5 | 2.0 |
Macrophage Inflammatory Protein-1/genetics | 2 | 15.0 |
Leukocytes, Mononuclear/cytology | 2 | 4.0 |
Adaptation, Biological | 3 | 23.0 |
HIV/immunology/*physiology | 2 | 10.0 |
Interferon Type II/*immunology | 2 | 5.0 |
Macrophage Inflammatory Protein-1/immunology | 2 | 25.0 |
RANTES/immunology | 3 | 50.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 4 | 1.0 |
RANTES/analogs & derivatives | 2 | 66.0 |
Receptors, Chemokine/*antagonists & inhibitors | 4 | 23.0 |
HIV-1/*drug effects/immunology | 2 | 18.0 |
Leukocytes, Mononuclear/drug effects/*metabolism | 2 | 5.0 |
Up-Regulation/drug effects/immunology | 2 | 5.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/metabolism | 5 | 9.0 |
HIV Envelope Protein gp120/chemistry/genetics/*metabolism | 2 | 25.0 |
Receptors, CXCR4/chemistry/*physiology | 2 | 100.0 |
Dendritic Cells/*immunology/*virology | 2 | 20.0 |
Interleukin-12/pharmacology | 2 | 4.0 |
Th1 Cells/*metabolism | 2 | 7.0 |
Gene Rearrangement | 2 | 0.0 |
Hematopoietic Stem Cells/physiology | 3 | 7.0 |
Protein-Tyrosine Kinase/physiology | 2 | 1.0 |
Receptors, Cytokine/*physiology | 4 | 15.0 |
Chemokines, CXC/metabolism/*pharmacology | 4 | 66.0 |
Down-Regulation/*immunology | 3 | 5.0 |
Chickens | 3 | 0.0 |
Protein Kinase C/*metabolism | 2 | 0.0 |
Immunity, Natural/*genetics | 2 | 12.0 |
HIV Antibodies/*immunology | 6 | 6.0 |
HIV-2/*metabolism | 4 | 28.0 |
HIV-1/*drug effects/genetics/physiology | 2 | 9.0 |
*Oncogenes | 2 | 0.0 |
S Phase | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
RNA, Small Interfering/*pharmacology | 2 | 22.0 |
HIV Envelope Protein gp120/drug effects/metabolism | 3 | 50.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
Interleukin-8/metabolism | 2 | 1.0 |
Liver Neoplasms/*metabolism | 2 | 2.0 |
Tumor Necrosis Factor-alpha/metabolism | 4 | 0.0 |
Ultraviolet Rays | 2 | 0.0 |
Lymphocytes/virology | 2 | 10.0 |
HIV-1/*drug effects/genetics/metabolism | 2 | 33.0 |
Luciferases/metabolism | 3 | 0.0 |
Viral Envelope Proteins/genetics | 2 | 8.0 |
Plasmids/genetics | 2 | 0.0 |
Central Nervous System/*metabolism | 2 | 5.0 |
Chemokines/metabolism/*physiology | 2 | 66.0 |
Neurons/metabolism | 2 | 0.0 |
Rodentia | 2 | 2.0 |
Mycobacterium avium Complex/*physiology | 2 | 100.0 |
Receptors, CXCR4/chemistry/physiology | 3 | 100.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/metabolism | 2 | 3.0 |
*Signal Transduction/drug effects | 2 | 2.0 |
Receptors, CXCR4/chemistry/*genetics | 2 | 100.0 |
Virus Replication/*genetics | 2 | 6.0 |
Acquired Immunodeficiency Syndrome/metabolism | 3 | 23.0 |
Blood Platelets/*metabolism | 2 | 0.0 |
Neutrophils/metabolism | 2 | 1.0 |
Hyperplasia | 2 | 0.0 |
Lung Neoplasms/secondary | 2 | 2.0 |
Magnetic Resonance Imaging | 3 | 0.0 |
Neoplasm Metastasis/drug therapy | 2 | 33.0 |
Alternative Splicing | 2 | 0.0 |
Endothelium, Vascular/cytology/*metabolism | 2 | 1.0 |
Fetal Blood | 2 | 1.0 |
*Hematopoiesis | 2 | 1.0 |
Megakaryocytes/cytology/*metabolism | 2 | 33.0 |
L-Selectin/*metabolism | 2 | 8.0 |
Fetal Blood/metabolism | 3 | 4.0 |
HIV Infections/immunology/metabolism | 2 | 22.0 |
Cyclic AMP/*metabolism | 2 | 0.0 |
Cyclic AMP-Dependent Protein Kinases/metabolism | 2 | 1.0 |
Receptors, CXCR4/*genetics/*metabolism | 2 | 50.0 |
*Genetic Vectors | 3 | 0.0 |
Receptors, Cytokine/physiology | 2 | 7.0 |
Receptors, Peptide/physiology | 2 | 25.0 |
Receptors, CXCR4/biosynthesis/immunology/*physiology | 3 | 100.0 |
Indicators and Reagents | 2 | 0.0 |
Macrophages/drug effects/*virology | 2 | 50.0 |
Cell Survival/immunology | 2 | 3.0 |
Chemotaxis, Leukocyte/drug effects/*immunology | 2 | 28.0 |
Molecular Weight | 2 | 0.0 |
Autoradiography | 2 | 0.0 |
Drug Resistance, Multiple | 2 | 1.0 |
Viral Envelope Proteins/genetics/*physiology | 3 | 33.0 |
Mitogen-Activated Protein Kinase 1 | 2 | 1.0 |
*Mitogen-Activated Protein Kinases | 3 | 0.0 |
SIV/*metabolism | 6 | 25.0 |
HIV-1/drug effects/*pathogenicity | 3 | 60.0 |
Membrane Fusion/immunology | 2 | 50.0 |
RANTES/*immunology | 2 | 50.0 |
Kidney/cytology | 2 | 1.0 |
Macrophages/physiology | 2 | 2.0 |
T-Lymphocytes/*physiology | 2 | 0.0 |
Interferon-alpha/*biosynthesis | 2 | 11.0 |
Membrane Proteins/biosynthesis/*metabolism | 2 | 15.0 |
Mice, Transgenic | 6 | 0.0 |
Fibroblast Growth Factor 2/metabolism | 2 | 2.0 |
Endothelium, Vascular/cytology/virology | 2 | 100.0 |
Cell Cycle | 4 | 0.0 |
Receptors, Cell Surface/genetics/metabolism | 2 | 3.0 |
Receptors, CCR5/*biosynthesis/immunology | 3 | 50.0 |
AIDS-Related Opportunistic Infections/virology | 2 | 50.0 |
Lymph Nodes/metabolism/pathology | 2 | 8.0 |
Antigens, CD4/*immunology/metabolism | 2 | 8.0 |
HIV-1/genetics/*pathogenicity/*physiology | 3 | 50.0 |
Receptors, CCR5/genetics/*physiology | 3 | 42.0 |
HIV Long-Term Survivors | 3 | 17.0 |
Receptors, CCR5/*biosynthesis/blood | 2 | 50.0 |
Receptors, CXCR4/*biosynthesis/blood | 2 | 100.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 3 | 0.0 |
CD4-Positive T-Lymphocytes/metabolism/virology | 2 | 15.0 |
Cytokines/*physiology | 4 | 2.0 |
Cell Movement/drug effects/immunology | 3 | 21.0 |
Gene Products, env/biosynthesis | 2 | 25.0 |
HIV Infections/*immunology/metabolism | 2 | 16.0 |
HIV-1/*immunology/metabolism | 2 | 25.0 |
Viral Envelope Proteins/*metabolism | 4 | 9.0 |
NF-kappa B/*metabolism | 3 | 0.0 |
Antigens, CD/genetics | 2 | 1.0 |
Complement 5a/pharmacology | 2 | 8.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 2 | 0.0 |
Models, Neurological | 2 | 1.0 |
Stem Cell Transplantation | 4 | 9.0 |
T-Lymphocyte Subsets/immunology/metabolism/virology | 2 | 100.0 |
Membrane Glycoproteins/immunology | 2 | 1.0 |
CD4-Positive T-Lymphocytes/*cytology/immunology | 2 | 8.0 |
CD8-Positive T-Lymphocytes/*cytology/immunology | 2 | 18.0 |
Leukocytes, Mononuclear/drug effects/metabolism | 2 | 3.0 |
Mucous Membrane/immunology | 2 | 7.0 |
Receptors, CXCR4/biosynthesis/*metabolism | 3 | 75.0 |
Receptors, HIV/biosynthesis/*metabolism | 2 | 100.0 |
Peptide Fragments/*immunology | 3 | 2.0 |
Cell Adhesion Molecules/analysis | 2 | 1.0 |
HIV/immunology | 2 | 3.0 |
Naphthalenesulfonates/*pharmacology | 2 | 100.0 |
DNA, Complementary | 3 | 0.0 |
Cytoplasm | 2 | 3.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*metabolism | 2 | 0.0 |
Transcription Factor AP-1/metabolism | 2 | 0.0 |
Receptors, CXCR4/*antagonists & inhibitors/genetics | 2 | 100.0 |
Brain Chemistry/*immunology | 2 | 33.0 |
Models, Immunological | 4 | 1.0 |
Electrophysiology | 2 | 0.0 |
Receptor Aggregation | 3 | 3.0 |
Receptors, Virus/physiology | 3 | 12.0 |
Simian Acquired Immunodeficiency Syndrome/immunology/*virology | 2 | 33.0 |
CD4-Positive T-Lymphocytes/*immunology/*virology | 2 | 13.0 |
Receptors, Cytokine/*genetics | 2 | 3.0 |
Hematopoiesis/*physiology | 3 | 3.0 |
Receptors, CXCR4/deficiency/genetics/*physiology | 2 | 100.0 |
Neovascularization, Physiologic/*physiology | 2 | 1.0 |
*Mutation | 6 | 0.0 |
Membrane Proteins/chemistry | 2 | 4.0 |
Actins/*metabolism | 2 | 0.0 |
Receptors, CXCR4/*analysis/physiology | 2 | 100.0 |
DNA Mutational Analysis | 3 | 0.0 |
*Cell Differentiation | 2 | 0.0 |
MAP Kinase Signaling System | 3 | 1.0 |
Receptors, Antigen, T-Cell/metabolism | 3 | 1.0 |
Microglia/metabolism/*virology | 2 | 40.0 |
Receptors, CCR5/immunology/*metabolism | 2 | 50.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Crosses, Genetic | 2 | 0.0 |
*SIV | 3 | 27.0 |
HIV-1/genetics/isolation & purification/*metabolism | 2 | 50.0 |
Transcription Factor, Sp1/metabolism | 2 | 0.0 |
Leukocytes, Mononuclear/cytology/immunology | 2 | 4.0 |
Luminescent Proteins/genetics/metabolism | 3 | 1.0 |
Leukocytes, Mononuclear/metabolism/virology | 2 | 25.0 |
Survival Analysis | 5 | 0.0 |
Simian Acquired Immunodeficiency Syndrome/*immunology | 2 | 11.0 |
HIV Envelope Protein gp120/genetics/*immunology | 2 | 10.0 |
RNA/genetics/metabolism | 2 | 1.0 |
Signal Transduction/genetics/*immunology | 2 | 2.0 |
Dendritic Cells/metabolism | 2 | 4.0 |
T-Lymphocytes, Cytotoxic/immunology | 3 | 0.0 |
Antibodies/metabolism | 2 | 2.0 |
*Chemokines, CC | 2 | 2.0 |
Receptors, CCR5/*genetics/*metabolism | 2 | 28.0 |
Tetradecanoylphorbol Acetate/metabolism | 2 | 6.0 |
Binding Sites, Antibody | 3 | 0.0 |
Receptors, CXCR4/*antagonists & inhibitors/immunology | 2 | 100.0 |
Membrane Proteins/*physiology | 3 | 2.0 |
Receptors, Antigen, T-Cell/immunology | 2 | 1.0 |
Membrane Proteins/genetics/*metabolism | 2 | 0.0 |
Receptors, Cytokine/genetics/*metabolism | 5 | 16.0 |
Models, Structural | 2 | 1.0 |
GTP-Binding Proteins/physiology | 2 | 3.0 |
Membrane Proteins/biosynthesis/*physiology | 2 | 33.0 |
Receptors, HIV/biosynthesis/*physiology | 2 | 100.0 |
Cell Survival/physiology | 2 | 1.0 |
Membrane Proteins/genetics/immunology/*metabolism | 2 | 20.0 |
Receptors, HIV/genetics/immunology/*metabolism | 3 | 100.0 |
Brain/*physiology | 2 | 1.0 |
Antigens, CD56/immunology | 2 | 14.0 |
HIV/physiology | 2 | 5.0 |
Antigens, CD3/metabolism | 3 | 1.0 |
Cytokines/*genetics | 2 | 1.0 |
Signal Transduction/drug effects/physiology | 2 | 0.0 |
Hematopoietic Stem Cell Transplantation | 3 | 1.0 |
Graft Survival | 3 | 0.0 |
Matrix Metalloproteinases/metabolism | 2 | 4.0 |
Models, Statistical | 2 | 1.0 |
Stem Cells/*physiology | 2 | 3.0 |
Receptors, CXCR4/genetics/immunology/*metabolism | 2 | 66.0 |
Receptors, CXCR4/antagonists & inhibitors/physiology | 2 | 100.0 |
Mitogen-Activated Protein Kinases/physiology | 2 | 1.0 |
Neurons/*physiology | 2 | 1.0 |
Fluorescence | 2 | 0.0 |
RNA, Messenger/analysis/metabolism | 2 | 1.0 |
Chemokines, CXC/*genetics/metabolism | 2 | 33.0 |
Interferon Type II/metabolism | 3 | 1.0 |
Fluorescent Antibody Technique/methods | 2 | 5.0 |
Protein Isoforms/genetics/metabolism | 2 | 1.0 |
Antigens, CD34/immunology | 2 | 3.0 |
Propylene Glycols/*pharmacology | 2 | 20.0 |
Cell Cycle Proteins/*metabolism | 2 | 0.0 |
Calcium/immunology | 2 | 20.0 |
DNA, Viral/chemistry/genetics | 2 | 20.0 |
DNA/genetics | 2 | 0.0 |
Pregnancy Trimester, First | 2 | 0.0 |
Melanoma | 2 | 2.0 |
CD4-Positive T-Lymphocytes/*metabolism/*virology | 2 | 100.0 |
Microcirculation | 3 | 1.0 |
Cytoskeleton/metabolism | 2 | 0.0 |
MAP Kinase Signaling System/immunology | 2 | 10.0 |
Virion/physiology | 2 | 8.0 |
Genes, env/*genetics | 2 | 33.0 |
*Recombination, Genetic | 2 | 0.0 |
Bone Marrow | 2 | 5.0 |
Stem Cells/cytology/*immunology | 2 | 28.0 |
Cell Movement/drug effects/*immunology | 2 | 14.0 |
Trophoblasts/cytology/*immunology | 2 | 28.0 |
Antibody Affinity | 2 | 1.0 |
Breast Neoplasms/*metabolism/pathology | 2 | 1.0 |
Cell Adhesion Molecules/*immunology | 2 | 3.0 |
*Genes, Reporter | 2 | 4.0 |
*Peptide Library | 2 | 3.0 |
Alkaline Phosphatase/metabolism | 2 | 1.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Chemokines, CXC/genetics/physiology | 3 | 100.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
RNA, Messenger/genetics/*metabolism | 2 | 1.0 |
Antigens, CD34/*blood | 2 | 2.0 |
*Hematopoietic Stem Cell Mobilization | 2 | 3.0 |
CD4-Positive T-Lymphocytes/*chemistry | 2 | 12.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Pertussis Toxin/pharmacology | 3 | 5.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
United States | 2 | 0.0 |
Rhinitis/immunology | 2 | 40.0 |
CD4-Positive T-Lymphocytes/cytology/drug effects/*immunology | 2 | 15.0 |
Acquired Immunodeficiency Syndrome/prevention & control | 2 | 16.0 |
*Cell Migration Inhibition | 2 | 5.0 |
HIV Infections/*prevention & control/virology | 2 | 40.0 |
Antigens, CD/biosynthesis | 2 | 0.0 |
Antigens, CD34/*biosynthesis | 2 | 4.0 |
*Neovascularization, Physiologic | 3 | 1.0 |
Cell Death | 2 | 0.0 |
Cytomegalovirus/immunology | 2 | 2.0 |
Cycloheximide/pharmacology | 3 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
Tonsil | 2 | 9.0 |
Galactosylceramides/metabolism | 2 | 14.0 |
HIV-1/immunology/*pathogenicity | 2 | 14.0 |
Receptors, CXCR4/analysis/biosynthesis | 2 | 100.0 |
Genes, Dominant | 2 | 0.0 |
Clone Cells/immunology | 2 | 1.0 |
Plasmids | 2 | 0.0 |
Receptors, CXCR4/*metabolism/physiology | 2 | 100.0 |
T-Lymphocytes/*immunology/virology | 2 | 11.0 |
HIV Infections/blood/*immunology/virology | 2 | 28.0 |
Retroviridae/genetics | 3 | 0.0 |
Drug Resistance, Viral | 2 | 3.0 |
Epidermal Growth Factor/metabolism | 2 | 0.0 |
Virus Assembly | 2 | 7.0 |
Leukemia Virus, Murine/*genetics | 2 | 13.0 |
